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 Dynamic contrast enhanced (DCE) imaging acquires time-lapsed images of 
intravenously injected contrast agents to quantify changes in their delivery to and 
clearance from the tissue. It is widely used in clinical imaging to assess tissue perfusion 
and vascular permeability. However, minimal work has been done using DCE in a 
murine model to better understand the effects of radiotherapy on the vasculature and 
tissue. This is due in part to a lack of DCE imaging systems with the resolution to directly 
observe the underlying changes in single-vessel structure and function. In this thesis, I 
develop and use macroscopic dynamic fluorescent imaging (DynFI) and microscopic 
quantitative multiphoton microscopy (QMPM). These DCE techniques identify changes 
in tissue perfusion several days after radiotherapy in the healthy bone marrow, leukemic 
bone marrow, and solid tumor tissue. DCE imaging can be performed using QMPM 
while simultaneously observing changes in the single-vessel characteristics for direct 
correlation. Using QMPM, changes in bone marrow vasculature were observed with the 
onset of acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Changes 
included increased angiogenesis, permeability, decreased mean vessel diameter, 
decreased single-vessel blood flow, and decreased drug delivery. For mice bearing ALL, 
this resulted in reduced cellular uptake of a chemotherapy surrogate. The results 
identified potential biomarkers for leukemia using DCE imaging. Treatments ranging 
from 2 Gy to 10 Gy of total body irradiation (TBI) increased single-vessel blood flow and 
drug delivery for mice bearing AML and ALL 2 to 5 days after TBI. For mice bearing ALL, 
targeted 2 and 4 Gy radiotherapy resulted in improved cellular chemotherapy uptake. 




4Gy TBI before chemotherapy compared to chemotherapy before 4Gy TBI. Finally, I 
develop DynFI with principal component analysis to rapidly identify changes in tumor 
vasculature before and 2 days after 10 Gy targeted radiotherapy. In conclusion, DCE 
analysis is an effective tool to measure tissue perfusion and vascular function. Increased 
availability of DCE imaging for preclinical models will allow for a better understanding of 
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feature values were assigned to the red and blue channels, respectively. Green intensities were 
set to zero. A clear change from blue to red can be seen from pretreatment to two days 
posttreatment, showing TVR. Box and whisker plots of normalized PC feature values for (e) PC1 
and (f) PC2 tumor and kidney ROIs from the corresponding pretreatment and two days 
posttreatment DynFI data. An increase in normalized PC1 feature values and a decrease in 
normalized PC2 feature values are seen in the tumor posttreatment, while no change is seen for 




 Figure 4-5: Box and whisker plots comparing the pre and two days posttreatment normalized (a) 
PC1 and (b) PC2 feature values for all four mice. The mean whole-tumor normalized (c) PC1 and (d) 
PC2 tissue values are shown along with the corresponding paired t-test. © 2020 IEEE ................ 104 
 Figure 4-6: Automated classification of TVR using a confidence covariance Ellipse algorithm. 
Scatter plots of normalized PC1 and PC2 feature values for (a) mouse two and (c) mouse three are 
shown. The normalized PC feature values from pretreatment images (PRE) are shown as black 
dots. The classification algorithm calculated a 99.9% confidence covariance ellipse (dashed line) 
from pretreatment data, which was used to classify the posttreatment pixels as TVRpos (blue) and 
TVRneg (red). Ambient-light posttreatment images of (b) mouse two and (d) mouse three with the 
overlaid tumor ROI pixels classified as TVRpos (blue) and TVRneg (red) are shown. © 2020 IEEE .... 105 
 Figure 5-1: A diagram of the healthy, leukemic, and leukemic irradiated BMV showing changes in 
vascular morphology, blood flow, vascular permeability, and drug delivery between healthy mice, 
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Chapter 1: Introduction 
1.1 Tumor vasculature and drug delivery 
1.1.1 The role of the vasculature in the tumor microenvironment 
 The vascular system is responsible for the delivery of oxygen and nutrients to the 
tumor microenvironment, where the rapid growth of tumor cells often creates high 
metabolic demand for oxygen and nutrients [1]. As a result, the formation of new vessels 
is critical for tumor progression. Tumor induced angiogenesis and vessel remodeling 
results in a variety of changes including vessel permeability, poor pericyte coverage,  
altered vessel diameter, and altered vessel spatial distribution [2-4]. Additionally, the 
tumor vasculature plays a direct role in supporting metastasis by allowing tumor cells to 
enter the blood and circulate to different regions of the body [5]. While vessel recruitment 
is necessary to support tumor growth, the unchecked angiogenesis of tumor supporting 
blood vessels results in heterogeneous vascular structures that have inadequate 
delivery of oxygen and poor chemotherapy delivery to tumor cells. This results in 
increased resistance chemotherapy and radiotherapy (RT) for many tumor cell types [6-
8].  
1.1.2 Vascular based strategies for the treatment of malignancies 
 In the last few decades, there has been increased emphasis on alternative 
combination-based therapies for the treatment of malignancies [9]. There are several 




improve treatment outcomes. One strategy involves damaging the vascular system to 
prevent delivery of oxygen and nutrients to malignancy to indirectly kill tumor cells [10, 
11]. Other strategies aim to improve the delivery of oxygen and therapeutics to tumor 
cells to make standard RT or chemotherapy treatments more effective [7, 12]. 
 The optimization of drug delivery is challenging because of the heterogeneity of 
malignant vasculature and the complex response of the vasculature to treatment [13]. To 
effectively optimize therapeutic delivery, both the pharmacokinetics of the therapeutics 
and the functional vascular characteristics (e.g., permeability, density, morphology, and 
blood flow) must be understood. Attempts to optimize the tumor vasculature on the basis 
of pharmacokinetics alone may result in further vascular dysfunction [12]. Alternatively, 
optimization based on solely the characteristics of the tumor vasculature does not 
account for the wide variety of sizes and types of therapeutics (targeted or non-targeted) 
[14]. Therefore, effective methods that simultaneously observe vascular functional 
characteristics and therapeutic pharmacokinetics are essential to condition the 
vasculature in combination therapy. 
 “Vascular normalization” is a strategy aimed at creating a more homogenous 
distribution of blood vessels in terms of vessel density, permeability, and blood flow by 
balancing proangiogenic and antiangiogenic signaling and other factors to improve drug 
delivery to malignancies [15]. This strategy has been used successfully in several solid 
tumor malignancies and has demonstrated how restoring the vascular structure to a 
state resembling healthy tissue improves standard chemotherapy delivery and treatment 
outcomes [16, 17]. However vascular normalization is challenging because of the 
number of pro-angiogenic pathways and the complex response of different individual 
tumor environments to treatment. Knowledge of the timing of optimal vascular 




combination with chemotherapy or RT, and methods of assessing vascular function are 
necessary, but not simple or straightforward [18]. 
 An alternative strategy to vascular normalization is the “pro-vascular” approach. 
Compared to healthy tissues, most solid tumors are characterized by tumor regions or 
entire tumors with poor vascular blood flow [19]. In solid tumors there is a combination of 
immature capillaries due to angiogenesis, and more mature vessels pre-existing 
capillaries, arterioles, and venules [20]. These mature vessels are often more capable of 
vasoconstriction and vasodilation than newly formed vessels [21, 22]. Provascular 
therapies exploit vasodilation of mature blood-supplying tumor vessels to transiently 
improve vessel blood flow and in turn improve the delivery of oxygen or chemotherapy. 
Examples of this include certain regimens of hyperthermia and regulation of nitric oxide 
and endothelin-1 to impact vasodilation [7, 23].  
 Compared to vascular normalization, pro-vascular strategies are less dependent 
on the optimization of the treatment regimen to “fine tune” the vascular response. 
Vasodilation can transiently increase blood flow and in turn directly enhance 
chemotherapy delivery. However, the heterogenous nature of tumor blood vessels may 
make this type of treatment ineffective for regions where there is low vascular density 
and does not necessarily promote homogenous blood flow and drug delivery through to 
the tumor [20].  
1.1.3 The response of the solid tumor vasculature to radiotherapy 
 Many studies have been performed measuring the impact of radiotherapy on the 
tumor vasculature and blood flow. However, the response of the tumor vasculature to 
radiotherapy is complex and depends on many factors such as dose, timing, and tumor 




treatment with 15 or 20 Gy radiotherapy compared to immediately after treatment. No 
differences were noticed in cell death following 10 Gy treatments. 20 Gy treatments also 
resulted in reduced tumor perfusion, and increased HIF-1α and VEGF after radiotherapy, 
suggesting that enhanced tumor cell death several days after radiotherapy may be due 
to vascular damage and poor vascular transport of oxygen [10]. Additionally other 
studies have noticed differences in the response of the tumor vasculature to 
radiotherapy dose and fractionation, with more severe longer lasting changes occurring 
at higher doses and minimal vascular changes occurring at doses of 10 Gy or less [24-
26]. A review by Park, et al. summarized the results of 43 representative studies on 
tumor vasculature and concluded that, in general, radiotherapy from 5-10 Gy in a single 
dose causes minimal damage, but higher doses than 10 Gy can induce severe vascular 
damage that reduce blood flow [11]. 
 At lower doses, several studies have noticed increases in vascular tumor 
perfusion after irradiation, either through vascular normalization or through transient pro-
vascular improvements in blood perfusion [27-30]. One study has demonstrated a pro-
vascular effect using low-to-moderate dose radiotherapy in mouse hepatocarcinoma 
tumors. Irradiation resulted in immediate vasodilation in tumor supporting arterioles for 2-
3 days which led to transient improvements in tumor perfusion and better tumor control 
with successive 6 Gy treatments. Vasodilation was shown to be directly dependent on 
increased endothelial expression of nitric oxide synthase and decreasing caveolin-1 
expression after irradiation [31]. These study demonstrates that the proper dose of RT 
has the potential to transiently improve vascular blood perfusion in solid tumor 
malignancies and demonstrates the variety of vascular responses that can occur 





1.1.4 The role of the bone marrow vasculature in the treatment of leukemia 
 While much work has been done studying the impact of the vascular system in 
the treatment of solid tumor malignancies, less work has been done developing vascular 
based treatment approaches for leukemia. This is in part due to the relatively large 
vascular blood volume and high blood flow in the healthy bone marrow [32] as well as 
the more systemic distribution of leukemia throughout the body. In preclinical studies, 
vascular leakiness, alterations in vascular structure, and angiogenesis have all been 
shown with the onset of leukemia. Studies have demonstrated that leukemia induced 
bone marrow vasculature (BMV) remodeling decreases chemotherapy delivery to 
leukemia cells residing in the bone marrow of mice bearing acute myeloid leukemia 
(AML) and that inhibition of leukemia induced BMV remodeling improves chemotherapy 
delivery and overall survival efficacy when used with chemotherapy [3, 8]. Additional 
studies using human AML have reported vascular alterations that result in poorly 
distributed blood flow, similarly to solid tumor models [2]. In patients with leukemia, 
angiogenesis is commonly observed [33] and increased hypoxia in the bone marrow has 
been reported, due in part to similar vascular alterations as seen in preclinical studies 
[34]. 
 Despite the success of anti-angiogenic therapies with some solid tumor 
malignancies, initial vascular based treatments that have attempted to normalize the 
leukemic BMV using anti-angiogenic therapies have not improved patient outcomes for 
leukemia [35, 36]. Several explanations for this are possible including; 1) multiple 
possible pathways for vascular regulation, 2) the complex response of the vascular 
system to treatment [37], and 3) a lack of methods to assess the treatment response of 




 While studies have been performed characterizing changes in the vascular 
system during RT in solid tumor malignancies, the effects of RT on the malignant BMV 
have not been characterized. This is likely because RT is not commonly used for the 
initial clinical treatment of many hematological malignancies. High-dose total body 
irradiation (TBI) treatments are used for several high-risk hematopoietic malignancies in 
patients, often as a myeloablative conditioning regimen prior to hematopoietic stem cell 
transplantation [38]. However, RT is not often considered for induction therapy in many 
hematopoietic malignancies like leukemia [39]. For induction therapy, non-myeloablative 
low-dose radiotherapy (LDRT) is a potential option for combination with chemotherapy 
and has several attractive benefits, including the radiosensitivity of hematological 
malignancies, the ability to precisely target regions of high disease burden, and lower 
toxicity compared to myeloablative high-dose RT [40, 41]. Such advantages make LDRT 
a possible candidate for combination therapy; however, the response of the BMV to 
LDRT is largely unknown and needs to be considered to optimize the delivery of 
therapeutics to the malignant bone marrow. 
1.2 Dynamic contrast enhanced imaging  
1.2.1 Dynamic contrast enhanced imaging tissue uptake and clearance 
 One effective clinical technique to assess the function of the tumor vasculature is 
dynamic contrast-enhanced (DCE) imaging with modalities such as magnetic resonance 
imaging (MRI) or computed tomography (CT), or macroscopic dynamic fluorescent 
imaging (DynFI). DCE imaging acquires time-lapsed images of intravenously injected 
molecular contrast agents to quantify changes in their delivery to the tissue [42]. 
Alterations in BMV function have been shown in hematological malignancies, tumor 




 Limitations to DCE imaging include; 1) inadequate resolution required to directly 
observe the features of capillary-sized vessels, making direct observations of the 
underlying vascular functional characteristics difficult or impossible[47], 2) the resolution 
makes it challenging to observe tracer uptake in the bone marrow of a mouse model, 
limiting usefulness in a preclinical setting for hematological applications.  
 Despite being unable to directly observe the underlying vascular characteristics 
using DCE imaging, features of the vascular structure can be quantified using the proper 
molecular contrast agents and time-lapsed imaging analysis methods. These changes 
can be quantified in several ways, including semi-quantitative descriptive curve analysis, 
and mathematical compartment modeling to obtain parameters such as vascular 
permeability, blood flow, vascular blood volume, and extravascular tissue space [42].  
1.2.2 Compartment modeling using the Toft model and semi-quantitative 
curve analysis 
 Compartmental kinetic modeling has been used frequently for clinical DCE 
imaging to understand changes in the tissue and vasculature that influence the uptake 
and clearance of molecular contrast agents. Several models have been developed for 
DCE imaging applications. For the intravital multiphoton microscopy imaging performed 
in this work, Toft’s model is used [48] which assumes no vascular volume is present in 
the tissue regions. The rate of exchange between the local vasculature and the tissue 
compartment assumes two-way passive equal transport of molecular contrast from the 
blood plasma, to the extravascular extracellular space through a semi-permeable 
membrane and is shown in Equation 1-1. Negligible cellular uptake of the molecular 
contrast and a constant total tissue volume is assumed. 
𝑑𝑑𝐶𝐶𝑡𝑡(𝑡𝑡)
𝑑𝑑𝑡𝑡
= (𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡) �𝐶𝐶𝑝𝑝(𝑡𝑡) −
𝐶𝐶𝑡𝑡(𝑡𝑡)
𝑣𝑣𝑒𝑒𝑒𝑒





Where 𝐶𝐶𝑝𝑝(𝑡𝑡) is the concentration of molecular contrast in the blood plasma of the 
local vasculature and 𝐶𝐶𝑡𝑡(𝑡𝑡) is the concentration of the extravascular tissue. Ktrans is the 
transfer rate of a molecular agent between the blood plasma and extracellular 
extravascular tissue. However, the extracellular extravascular tissue region cannot be 
directly identified from images, so the fraction of the extravascular space that is 
extracellular (νec) is solved for using the model to account for changes in tissue 
cellularity. An additional term Kep is called the backflux rate and identifies the rate of 
transfer from the extravascular tissue compartment to the blood plasma for a given 
tissue concentration. It is equal to Ktrans/ νec (Figure 1-1).
 
Figure 1-1: Two diagrams illustrating the Toft model and primary parameters Ktrans, 
νec, and Kep. The diagram on the right illustrates the blood plasma in red, extravascular 
extracellular tissue in blue, and extravascular cellular tissue region as black circles.  
 One additional model that has relevance to the bone marrow  is the extended toft 
model [48], which accounts for changes in the vascular volume within the whole bone 
marrow tissue by adding a term into the model for fractional vascular volume. However, 
an initial estimate of the fractional vascular volume must be made to fit the extended toft 
model directly to the extravascular tissue concentration instead of the whole tissue 
concentration (blood and tissue regions combined). For imaging of the bone marrow in 




been made, making validation of any estimates challenging. Furthermore, observations 
of large relative differences in vascular volume between the femur and calvarium bone 
marrow tissues have been made [49], making estimates in blood volume in other bone 
marrow regions irrelevant for estimating the blood volume the calvarium [50]. For these 
reasons, we chose to analyze the data using the Toft model rather than the extended 
Toft model in this work.  
 For all multiphoton microscopy data in this work, a value of 0.4 for the hematocrit 
was used to convert the molecular contrast concentration in the vascular tissue to 𝐶𝐶𝑝𝑝(𝑡𝑡). 
𝐶𝐶𝑝𝑝(𝑡𝑡) is modeled by a summation of two separately weighted exponential decay curves 
(Equation 1-2). This allows accurate function fitting to plasma concentration data when 
renal clearance and leakage of molecular contrast into tissues throughout the body are 
occurring at different rates. 
 𝐶𝐶𝑝𝑝(𝑡𝑡) = ∑ [(𝐴𝐴𝑖𝑖)(𝑒𝑒−𝜇𝜇𝑖𝑖∗𝑡𝑡)]2𝑖𝑖=1  (1-2) 
Where 𝐴𝐴𝑖𝑖 and 𝜇𝜇𝑖𝑖 are the scaling coefficient and attenuation coefficient for the ith 
exponential plasma concentration curve, respectively. Substituting  Equation 1-2 into 
Equation 1-1 and setting the initial tissue concentration equal to zero to obtains Equation 
1-3. 
 𝐶𝐶𝑡𝑡(𝑡𝑡) = 𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ∑ ��
𝐴𝐴𝑖𝑖
(𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ν𝑒𝑒𝑒𝑒⁄ )−μi
� �𝑒𝑒−μi∗t − 𝑒𝑒−(𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 ν𝑒𝑒𝑒𝑒⁄ )∗𝑡𝑡��2𝑖𝑖=1   (1-3) 
The vascular and extravascular tissue regions of images are identified and the 
mean signal intensity from these regions is calculated. The mean signal intensity is 
proportional to the molecular concentration for fluorescent imaging. A1, A2, μ1, and μ2 
can be identified by fitting Equation 1-2 to the blood plasma concentration data through 
error minimization algorithms. Once A1, A2, μ1, and μ2 are known, they can be 
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incorporated in to Equation 1-3 to identify Ktrans, νec, by fitting the equation to the 
extravascular tissue concentration data through least square fitting.  It can be shown that 
Ktrans is approximately equal to the average vascular permeability times the average 
vascular surface area per volume of tissue when the majority of the initial molecular 
contrast just after intravenous injection remains in the vasculature tissue and does not 
entirely permeate into the tissue bed before reaching the veins [48] (Equation 1-4). This 
will be true in cases where the relative leakage rage of molecular contrast is much 
slower than the contrast flow through the vasculature (i.e. large sized molecular contrast 
and well perfused tissue such as the bone marrow). 
𝑃𝑃𝑒𝑒𝑃𝑃𝑃𝑃𝑒𝑒𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑡𝑡𝑃𝑃 = 𝐾𝐾𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
𝑉𝑉𝑡𝑡𝑡𝑡𝑉𝑉𝑉𝑉𝑉𝑉𝑡𝑡𝑡𝑡 𝑆𝑆𝑉𝑉𝑡𝑡𝑆𝑆𝑡𝑡𝑉𝑉𝑆𝑆 𝐴𝐴𝑡𝑡𝑆𝑆𝑡𝑡
  (1-4) 
 Clinical DCE imaging will identify 𝐶𝐶𝑝𝑝(𝑡𝑡) through contouring of an arterial input 
function and sampling the concentration of the arterial blood. However, this is not 
possible for microscopic imaging methods, where only the local vasculature in the tissue 
can be observed. Differences between the arterial blood and local blood molecular 
contrast concentrations are possible, making direct comparisons between macroscopic 
and microscopic modeling parameters challenging. In the case of high blood flow with 
slow leakage of contrast to the extravascular tissue (i.e. blood flow>>vascular leakage 
rate), the arterial blood concentration will be equal to the vascular tissue blood 
concentration and the modeling parameters can be directly compared. Alternatively, in 
the case of low blood flow and fast leakage of contrast to the extravascular tissue (i.e. 
blood flow<< vascular leakage rate), the arterial blood concentration will not match the 
vascular tissue blood concentration before the extravascular tissue concentration 
reaches steady state with the arterial blood plasma concentration. In this context, 
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modeling using arterial blood or the vascular tissue blood concentration to solve for Ktrans 
will give different results.
1.2.3 The effects of total body irradiation on DCE imaging 
 No work has been published using clinical DCE imaging in the bone marrow of 
patients receiving TBI. DCE imaging using MRI has been able to detect increased peak 
contrast uptake in the bone marrow after TBI using a macromolecular iron contrast agent 
1 to 2 days after completion of 3 fractions of 4Gy TBI in rabbits [51]. Additional studies 
observed increased Ktrans, and νec 4 to 7 days after 6 Gy TBI treatments in rats using the 
extended Toft’s model with a small molecular weight gadolinium-based contrast agent 
(MultihanceTM). Decreases in Kep and blood volume were also observed [52]. Such 
observations suggest increased vascular permeability and/or increased vascular surface 
area due to vascular damage. 
1.2.4 Clinical DCE imaging for leukemia and lack of preclinical translation 
 DCE-MRI imaging with a small molecular weight (938 Da) gadolinium contrast 
agents in patients with AML after standard induction chemotherapy has been shown to 
have predictive value for disease-free survival [43], demonstrating the prognostic value 
of DCE imaging for leukemia. DCE imaging using the same contrast agent has also 
identified increased contrast peak height and wash-in slope (rate of initial accumulation) 
in the bone marrow of patients with AML compared to healthy volunteers [53]. Increased 
blood flow and blood volume have been proposed as reasons for changes in peak 
height and wash-in slope, respectively. However, the results of these experiments are 
not in agreement with observations of poor chemotherapy delivery in mice bearing 
leukemia shown in section 1.1.4. Additionally the causes behind changes in contrast 
uptake and clearance are not always easily interpreted as they depend on many factors 
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such as BMV permeability, BMV surface area, diffusion, convection and interstitial 
pressure [54]. The relatively poor spatial resolution of clinical imaging modalities 
combined with the known vascular heterogeneity in areas of malignancy highlight the 
need for better preclinical methodologies to interpret clinical imaging. A quote from Jain 
et al. [12] in one of the primary publications regarding vascular normalization treatment 
summarizes this problem: 
“As we interpret these human data obtained from MRI, PET, and CT, two key 
limitations of these imaging methods must be kept in mind. First, because most of these 
methods yield a parameter that depends on both blood flow and permeability [Ktrans], the 
blood flow and permeability cannot be calculated unambiguously. Second, tumor blood 
flow is highly heterogeneous. It is not the total blood flow, but the distribution of blood 
flow, that determines the distribution of a drug or oxygen in tumors. Therefore, the global 
(total) blood flow, as estimated by the currently available resolution of MRI, CT, or PET, 
does not inform us about the degree of spatial heterogeneity in vascular normalization or 
drug distribution... Thus, improved imaging techniques, which can measure the spatial 
and temporal changes in blood flow and other physiological parameters with higher 
resolution, are needed to definitively establish the effects of antiangiogenic treatment on 
vascular function in human tumors growing at different sites.” 
 The lack of agreement between clinical and preclinical information demonstrate 
the need for preclinical methodology capable of performing clinically relevant contrast-
based time-lapsed imaging, while directly observing BMV alterations and tissue drug 
uptake at the single-vessel resolution. This would allow a better understanding of the 
underlying factors influencing DCE imaging and ensure accurate interpretations of 
changes in DCE parameters found in patients with AML. 
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1.3 Intravital fluorescent multiphoton microscopy 
1.3.1 Intravital calvarium imaging 
 In the previous sections, the need for vascular imaging techniques at higher 
resolution to better understand the effectiveness of vascular based treatments is 
outlined. Intravital fluorescent multiphoton microscopy is one such approach that can be 
used to observe the small bone marrow compartments in the calvarium in mice. This 
approach has been shown to be an effective way to observe bone marrow related 
changes in live mice. The calvarium bone region is used because 1) it contains 
sinusoidal vessels similar to those in other hematopoietic bone marrow regions [55, 56], 
2) it has similar proportions of hematopoietic stem cells and similar hematopoietic
reconstitution potential compared to bone marrow regions that are considered the 
primary sites of hematopoiesis [49], and 3) it is a flat, thin, superficial bone requiring 
minimal invasive surgery before live imaging. Many studies have utilized intravital 
calvarium imaging to observe changes in vascular morphology, single-vessel blood flow, 
and vascular permeability with the onset of leukemia as well as for other bone marrow 
related applications [2, 3, 8, 49, 56, 57].  
1.3.2 Dynamic multiphoton microscopy to measure vascular permeability 
and drug delivery 
 Fluorescent multiphoton imaging is one microscopy technique that has gained 
popularity for intravital imaging in the last several decades. Compared to standard 
fluorescent confocal microscopy, multiphoton microscopy has several advantages 
including 1) increased imaging depth, 2) reduced out of field phototoxicity, and 3) the 
acquisition of second harmonic generation from the collagen in the bone of the calvarium 
[58, 59]. 
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 Fluorescent dextran conjugates of a variety of molecular weights are commonly 
used for multiphoton microscopy as a contrast agent. Vascular leakage of dextran with 
molecular weights up to 150 kDa has been observed in the bone marrow [3] due to the 
presence of highly permeable sinusoidal vessels [57].The macromolecular size of 
150kDa dextran makes it ideal for measurements of vascular permeability [3, 57]. In 
comparison to 150 kDa sized dextran, 4kDa sized dextran rapidly permeates the BMV, 
and it is closer in molecular weight to typical chemotherapies used in the treatment of 
leukemia such as daunorubicin (563.98 Da) or cytarabine (243.22 Da) [39]. It is 
additionally closer in size to clinically used gadolinium-based contrast agents for DCE 
imaging with MRI (Gd-DTPA  547.6 Da). Compared to chemotherapy, 4kDa dextran has 
a minimal effect on the bone marrow microenvironment [60], making it ideal for 
longitudinal studies as a drug surrogate and is useful for comparison with DCE imaging. 
 While multiphoton microscopy has the resolution to distinguish between the 
blood and tissue regions, analysis of vascular leakiness is typically done in a semi-
quantitative fashion [61] or by obtaining the slope of the ratio of the extravascular tissue 
signal intensity to the blood signal intensity after injection of molecular contrast agents 
and equating that ratio to vascular permeability [3, 62]. However, this ratio method is 
only accurate very early after contrast injection, when the accumulation of contrast in the 
extravascular tissue space is minimal. Additionally, it cannot identify the extravascular 
extracellular tissues space parameter, which is dependent on cellularity and changes 
dramatically during RT. Models like the Toft’s model or extended Toft’s model[48] can be 
applied to multiphoton microscopy to identify the extravascular extracellular space and to 
make dynamic microscopy imaging more quantitative. Additionally, the use of these 
models with microscopy may give insight into the accuracies of commonly used MRI 
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based modeling approaches through direct visualization of the vascular and 
extravascular tissue regions [47]. 
1.3.3 Assessments of single-vessel blood flow 
 An additional advantage of multiphoton microscopy is its ability measure the 
velocity of cells flowing through the individual blood vessels. Several works have used 
measurements of the velocity of cells flowing through the vasculature as measurements 
of single-vessel blood flow. This can be done using scanning confocal or multiphoton 
microscopy by using repeated scans in parallel with the center of the vessels after 
molecular fluorescent contrast has been injected (Figure 1-2) [56]. Cells in the blood 
vessels are observed as dark streaks on plots of position versus time. A correction factor 
is often applied to measurements to account for differences between the central velocity 
of cells and the corrected mean velocity of cells flowing through the microvasculature 





 Where Vcenterline is the velocity of cells as measured at the center of the measured 
vessel. 𝛼𝛼 is a correction factor calculated from the vessel diameter (D) by Equation1-6. 
  𝛼𝛼 = 1.3 𝑤𝑤ℎ𝑒𝑒𝑒𝑒 𝐷𝐷 < 10𝜇𝜇𝑃𝑃  
𝑃𝑃𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃𝑃𝑃 𝑒𝑒𝑒𝑒𝑡𝑡𝑃𝑃𝑃𝑃𝑒𝑒𝑒𝑒𝑃𝑃𝑃𝑃𝑡𝑡𝑃𝑃𝑒𝑒𝑒𝑒 1.3 < 𝛼𝛼 < 1.6 𝑤𝑤ℎ𝑒𝑒𝑒𝑒 10𝜇𝜇𝑃𝑃 < 𝐷𝐷 < 15𝜇𝜇𝑃𝑃   
𝛼𝛼 = 1.6 𝑤𝑤ℎ𝑒𝑒𝑒𝑒 𝐷𝐷 > 15 𝜇𝜇𝑃𝑃 (1-6) 
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Figure 1-2: (A) An image of the BMV in the calvarium of a mouse injected with a 
fluorescent molecular contrast agent. The red arrow indicates the region designated to 
perform repeated centerline blood vessel scanning by the multiphoton microscopy 
system. (B) A diagram of repeated centerline blood vessel scanning showing a cell 
(black) flowing through a vessel with fluorescent contrast scanned repeatedly by the 
excitation laser (red). (C) As the cell moves through the vessel they will show up as dark 
streaks on the position versus time plot for the centerline scan of the vessel depicted in 
A.
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Chapter 2: QMPM imaging of the leukemic 
bone marrow vasculature reveals benefits of 
low-dose radiotherapy 
This chapter is based largely on the following published work: Brooks J, Kumar B, 
Zuro DM, Raybuck JD, Madabushi SS, Vishwasrao P, Parra LE, Kortylewski M, 
Armstrong B, Froelich J, Hui SK. Biophysical Characterization of the Leukemic Bone 
Marrow Vasculature Reveals Benefits of Neoadjuvant Low-Dose Radiation Therapy. Int 
J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):60-72. doi: 10.1016/j.ijrobp.2020.08.037. 
2.1 Introduction 
 In the previous chapter, clinical DCE imaging using either MRI or CT was 
identified as effective for characterization of some parameters pertaining to the BMV, 
however it lacked the resolution necessary to observe the underlying single-vessel sized 
BMV characteristics for direct correlation. To address the need for a single imaging 
platform capable of observing the BMV functional characteristics and pharmacokinetic 
alterations from RT, we developed and validated compartmental modeling for 
quantitative multiphoton microscopy (QMPM) time-lapsed imaging of the BMV in the 
calvarium of live mice bearing GFP+ Philadelphia chromosome B-cell acute 
lymphoblastic leukemia (ALL). For QMPM, time-lapsed images of 150 kDa fluorescent 
dextran leakage from the vascular lumen to the interstitial tissue were fit to the 




and νec. 150 kDa dextran was chosen as it has a slower leakage rate than smaller sized 
molecular contrast agents, making it a better molecular contrast agent to identify 
vascular permeability. Single-vessel functional BMV characteristics including single 
vessel blood flow, functional vessel surface area, vascular morphology, and vascular 
density were also measured.  
   After seeing changes in the BMV with the onset of ALL, we hypothesized that 
LDRT (2-4Gy) may improve vascular function and morphology, as well as reduce 
leukemic burden, leading to better uptake of therapeutics and enhanced efficacy when 
used as a neo-adjuvant therapy prior to therapeutic treatment. The response of the BMV 
to LDRT in mice bearing ALL was assessed using two treatment types 1) targeted LDRT 
to half of the calvarium and to the left femur (tLDRT) and 2) TBI. tLDRT was used to only 
irradiate small volumes of interest ensuring that the systemic blood flow of the 
cardiovascular system was not affected with treatment. To assess the uptake of 
therapeutics, cellular uptake of fluorescent agents in regions receiving tLDRT and 
matching regions outside of the radiation field (abscopal) were compared to assess 
therapeutic delivery. Assessments were made two days after tLDRT and 20 minutes 
after intravenous injection of Hoechst 33342 dye (Hoechst, MW: 615.99) or daunorubicin 
HCL (daunorubicin, MW: 563.98), a chemotherapy used in the treatment of ALL and 
other hematological malignancies [65]. Both agents are of similar size to many small 
sized therapeutic agents used for the treatment of hematological malignancies [39]. 
Finally, the efficacy of nilotinib (MW: 529.52),a similar sized therapeutic agent effective 
for the treatment of ALL [65], was administered before or after 4Gy TBI to determine 
whether LDRT-related changes to the malignant bone marrow and BMV may have an 
impact on treatment outcome in combination therapy. 
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2.2 Methods 
2.2.1 Mice, cell lines, and drug treatments 
 All procedures for animal experimentation were performed according to City of 
Hope guidelines and approved by the Institutional Animal Care and Use Committee. 
C57BL/6J mice (Strain 000664, Jackson Laboratory, Bar Harbor, ME) mice were 
injected with 1x106 GFP+ BCR-ABL (p190Kd) expressing B-cell ALLcells [66], 
suspended in 200 µl of phosphate buffered saline, through the tail vein. To test drug 
delivery, injection concentrations of 10 mg/kg and 40 mg/kg were used for fluorescent 
Hoechst 33342 dye (ThermoFisher Scientific Waltham, MA) and fluorescent 
daunorubicin HCL (Selleck Chemicals LLC Houston, TX), respectively. Mice were 
imaged or euthanized for tissue processing 20 minutes after tail vein injection of Hoechst 
dye or daunorubicin. Nilotinib (LC Laboratories Woburn, MA) treatments for survival 
studies were given at 50 mg/kg using oral gavage.  
 Eight-to-ten week-old female mice were used in experiments pertaining to 
endothelial cell analysis, QMPM tile image acquisition, and QMPM vessel morphology 
analysis. Experiments pertaining to vascular compartmental modeling, dextran well 
counter fluorescence, total bone marrow cell counts, and Hoechst dye uptake were 
performed using 7-10 week-old female mice. Intravascular cellular velocity 
measurements were performed using 7-12 week-old female mice. Daunorubicin QMPM 
imaging and daunorubicin cellular uptake assays were performed using 10-12 week-old 
male mice at moderate ALL burden (10-50% femur engraftment). Survival study 
experiments were performed using 8 week-old female mice. The age range of mice used 




 Mice for survival studies were monitored for disease progression by peripheral 
blood sampling. Survival study treatment intervention started seven days after ALL 
injection when ALL was detectable in the blood of all the mice. Nilotinib treatment was 
administered using oral gavage at 50 mg/kg suspended in 100 µl of 79% phosphate 
buffered saline and 21% DMSO. Mice not receiving nilotinib were administered 100 µl of 
79% phosphate buffered saline and 21% DMSO on matching days.  
2.2.2 Mouse surgery, multiphoton image acquisition, and image display 
 For QMPM imaging, mice were anesthetized initially with 3% isoflurane at a flow 
rate of 2 L/min, and then maintained with 1.5% isoflurane at a flow rate of 1.5 liters per 
minute. A stereotactic apparatus with a bite bar was utilized to keep the mouse stable 
during surgery. The skin and membrane above the calvarium were removed, and a 
custom titanium head plate with an inner diameter of 8 mm was fixed to the calvarium 
using Alpha-Dent Polycarboxylate Cement (Dental Technologies, Lincolnwood, IL). The 
head plate was then inserted into a custom built heated stage maintained at 37°C 
allowing for easy viewing of the mouse calvarium [67].  
 For QMPM imaging, a Prairie Ultima multiphoton microscope (Bruker Corporation 
Billica, MA) was used. QMPM imaging was primarily performed on the frontal bone 
region of the calvarium, however 2-3 mice with high leukemic burden were imaged on 
the superior parietal bone near the coronal suture, as ALL-induced bone degradation 
made imaging difficult on the frontal bone region. All imaging in this chapter was 
performed at single-day time points and mice were euthanized after imaging sessions.  
 Fluorescent excitation was performed using a Chameleon Ultra II tunable 
Ti:Sapphire laser with 140 femtosecond pulses (Coherent, Santa Clara, CA). An 
Olympus XLUMPlanFL 20x objective (1.00 NA water objective) was used for image 
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acquisition of all images. Simultaneous four channel acquisition was performed at 
660/40 (far red), 595/50 (red), 525/50 (green), and 460/50 (blue) for visualization of ALL, 
blood pool agents and second harmonic generation from the collagen in the bone. Data 
acquisition using the Prairie Ultima microscope was handled by Prairieview 5.3 software 
and imaging was performed at room temperature.  
 Vascular blood pool imaging was performed with intravenous injections of 20 µL 
of Qtracker™ 655 Vascular Label (Invitrogen, Carlsbad, CA) mixed with 80-180 µL of 
phosphate buffered saline. For time-lapsed imaging and measurements of permeability, 
Ktrans, and νec, mice were intravenously catheterized [61] and injected with 500 µg of 
150kDa TRITC dextran (TdB Consultancy, Uppsala Sweden) during image acquisition. 
Second harmonic generation imaging was used to observe pockets of calvarium marrow 
within the bone. Second harmonic generation of collagen co-localized with the bone 
regions surrounding the calvarium marrow compartment.  
 Fluorescent excitation was performed at 900 nm for GFP+ ALL fluorescence, 
150kDa TRITC dextran fluorescence, and Qtracker™ 655 Vascular Label fluorescence 
(acquired in the green, red, and far red channels respectively). Additional excitation was 
performed at 840 nm and 960 nm for visualization of both daunorubicin fluorescence 
(red channel) and GFP+ ALL fluorescence (green channel), respectively. The second 
harmonic generation image of the collagen in the bone was performed at 900 nm and 
960nm and was detected in the blue channel.  
 Comparison imaging of 4kDa TRITC dextran was performed with injections of 
350 µg suspended in 100 µl of phosphate buffered saline. Time lapsed imaging of 4kDa 




 Color channel windows were adjusted individually in Fiji/ImageJ to improve 
image display quality. Individual color window adjustments were identical between sets 
of comparative images. Static image processing and tiling of large image sets were 
performed using Fiji/ImageJ [68] and CellProfiler (v.2.2.0) [69].  
 Tiled images were acquired by collecting approximately a 5x4 grid series of 
overlapping z-stack images. The images were overlapping by 15% with a resolution of 
512 by 512 pixels and a z-slice spacing of 15 µm. Tiled images were stitched together 
using a Fiji/ImageJ grid collection/stitching plug-in [70]. Vascular diameter and the 
number of vessel branches per area were quantified using Fiji/ImageJ.  
 Image subtraction and cellular segmentation was performed using Cell Profiler. 
Image subtraction was used for quantitative GFP+ ALL and static daunorubicin 
fluorescence analysis as well as for the presentation of all images except time-lapsed 
daunorubicin and time-lapsed dextran image sets. Image subtraction minimized signal 
due to background fluorescence, which came from auto-fluorescent cells and collagen 
and is present in several acquisition channels. For image display and quantification of 
GFP+ ALL fluorescence in images acquired at 900 nm excitation, auto fluorescence from 
blue and red channels were multiplied by a scalar and subtracted from the green 
channel to eliminate signal from both collagen and auto-fluorescent cells respectively. 
For image display and quantification of daunorubicin and GFP+ ALL fluorescence in 
single time-point image sets, image subtraction was performed by multiplying the 840 
nm excitation blue channel signal by a scalar and subtracting from the 960 nm excitation 
green channel and 840 nm excitation red channel to identify GFP+ ALL and daunorubicin 
fluorescence, respectively. Healthy mice without daunorubicin injections were used to 
determine image subtraction scalars.  
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 Uncorrected centerline velocities of cells flowing through the BMV network were 
measured using QMPM and calculated in a similar fashion as in previous works [56, 57]. 
Vessel cellular velocities were measured after injection of either 150 kDa TRITC dextran 
or Qtracker™ 655 Vascular Label. Repeated line scans were taken transaxially on the 
center of blood vessels with frequencies of approximately 0.4 to 3 kHz. The average 
slope of 3 separate cells was found from time-space images using Fiji/ImageJ to 
calculate intravascular cellular velocity for a given vessel. 
2.2.3 Time-lapsed image acquisition and analysis 
 Time-lapsed single or z-stack images of dextran leakage into the tissue were 
taken initially with 6-15 second intervals, increased to approximately 60 seconds after 
peak tissue concentration had been reached for 150 kDa TRITC dextran. Image drift 
over time was accounted for by co-registration of time frames in Matlab® (R2018a 
9.41.0.81364, MathWorks Natick, MA). To identify blood and tissue compartment 
regions, time-lapsed images of dextran were cropped to in focus regions. The first frame 
after dextran had completely perfused the vasculature was selected to perform vascular 
segmentation in Fiji/Imagej. Images were smoothed with a median filter of four pixels in 
diameter and an Otsu’s thresholding algorithm [71] was applied to segment the 
vasculature from the tissue and background. If a single Otsu’s thresholding algorithm 
was not adequate to properly identify the vasculature, the first thresholded region was 
removed from the smoothed image and a second Otsu’s thresholding algorithm was 
applied to identify the remaining vascular regions. After vascular segmentation, an 
image frame after the dextran tissue concentration had reach maximum (typically the 
100th frame) was selected. A Gaussian filter of four pixels in diameter was applied to the 
image and the vascular regions found earlier were removed from the image. Another 




background. Since spatial overlap in the dextran fluorescent signal of blood and tissue 
compartments occurred primarily near boundary pixels in the region of interest (ROI), 
four- and eight-pixel erosions to the edges of the vascular and tissue ROI were 
performed respectively. This better isolated dextran fluorescence from tissue and blood 
compartments. After applying Otsu’s thresholding, regions of obvious segmentation 
mismatch were identified and removed, as such regions would significantly affect 
quantification accuracy. In general, needed removals were less than 10% of the total 
segmented volume (Figure 2-3). For daunorubicin compartment identification, blood and 
tissue compartments were identified in similar fashion as dextran compartments, while 
the daunorubicin cellular compartment was identified using simple manual selection of 
representative cellular signal at a late time point after blood and tissue clearance.  
 Dextran fluorescent intensity in blood and tissue compartments was quantified 
after spectral unmixing of GFP+ ALL signal bleed through into dextran signal calculated 






  (2-1) 
 Where R(t) and G(t) are the total red and green channel signal intensity at time t 
for the ROI. RB and GB are the background signal intensities prior to dextran injection for 
the red and green channels, respectively. A is the area of the ROI being analyzed. The 
equation for spectral unmixing was used to account for photobleaching of GFP+ ALL 
cells during time-lapsed imaging. Daunorubicin and 4 kDa TRITC dextran time-lapsed 
quantification was performed using pre-injection signal background subtraction rather 
than spectral unmixing, as minimal amounts of ALL signal was present in the 
daunorubicin channel. 
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 Dextran leakage from tissue and blood ROIs was modeled using Equation 1-3. 
The blood region was well described by the model using bi-exponential decay (only 
negative exponential terms were input). Good agreement between data and fit was 
obtained for all mice. Curve fitting was performed in Matlab® using the lsqnonlin() 
function. The fitting was performed from a range of starting conditions across the 
acceptable boundary conditions to ensure the error function was globally minimized.  
 Vascular permeability was calculated by dividing Ktrans by vessel surface area per 
imaging volume. The length and diameter of the lumen for each vessel was measured 
manually in Fiji/ImageJ, and the respective surface area was calculated by 
approximating vessels as cylinders. The amount of available calvarium marrow space in 
each imaging area was accounted for by observation of the second harmonic generation 
image of the collagen in the bone. 
2.2.4 Blood pressure measurements 
 Pulse rate, systolic blood pressure, and diastolic blood pressure measurements 
were acquired by tail cuff method on conscious mice using the BP-2000 Blood Pressure 
Analysis System (Vistech Systems). Thirty successive tail cuff measurements were 
taken on each day. The first 10 measurements were discarded to allow time for mice to 
grow accustomed to the tail cuff. Successful measurements from the last 20 
measurements were averaged together to obtain results. 
2.2.5 Computed tomography and LDRT treatments 
Computed tomography (CT) images were administered and acquired with the 
Precision X-RAD SMART Plus / 225cx small animal image guided irradiation system 
(Precision X-Ray, North Branford, CT) [72]. CT skull imaging was performed with 40 




shape the treatment beam field. CT image processing, contouring, and visualization 
were performed with Vivoquant (Invicro, Boston, USA) software. Dose calculations were 
performed by the small animal RT planning system [72], using a Monte Carlo dose 
engine [73, 74].  
 Mice were administered tLDRT treatments in a single-fraction of 2-4 Gy soft-
tissue-equivalent dose to the left half of the calvarium and left femur. Treatment was 
performed at 255 kVp and 13 mA. For calvarium treatment, the edge of an anterior 10 
mm square beam treated the calvarium with a soft-tissue-equivalent dose of 2 Gy or 4 
Gy. This resulted in a dose of approximately 5 Gy or 10 Gy to treated calvarium bone 
respectively as calculated using the Monte Carlo simulated treatment planning software 
on the small animal image guided irradiation system. This dose enhancement is largely 
due to the increased effective atomic number of bone compared to soft tissue. At an 
effective treatment photon energy of 78.8keV there will be increased dose absorption in 
bone compared to soft tissue due to photo-electric based dose absorption. The beam 
was placed 200 µm to the mouse’s right side from the sagittal suture and completely 
covered the parietal and frontal bones on the mouse’s left side. The left femur was 
treated with 10 mm square anterior to posterior and posterior to anterior beams. Dose 
was normalized to 2 Gy or 4 Gy 2 mm below the surface of the skull for parietal beam 
and 2 Gy or 4 Gy within the marrow for the femur beams.  
 tLDRT treatments were used to assess drug delivery and disease burden by 
comparing treated regions (left femur and left half of the calvarium) and abscopal 
regions (right femur and right half of the calvarium). TBI single-fraction treatments of 2-4 
Gy were administered at matching soft-tissue doses to tLDRT treatments, enabling 
comparisons of the irradiated BMV in the left half of the calvarium for tLDRT treatments 
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(local vascular treatment) and TBI treatments (systemic cardiovascular treatment). 
QMPM imaging and tissue harvests were performed 40-48 hours post-irradiation. 
2.2.6 Flow cytometry 
 Endothelial cell analysis was performed according to Kumar et al [75]. The tibias 
and femurs from mice were crushed and incubated with collagenase (3 mg/ml, Sigma 
Aldrich, St Louis, MO) for 45 min at 37°C to liberate the leukemic and bone marrow 
microenvironment cells from the bone surface. Cells were incubated with ACK lysis 
buffer (Gibco) for 5-10 minutes and washed with phosphate buffered saline. The cells 
were filtered through a 40 μm filter and centrifuged at 300xg for 5 min with phosphate 
buffered saline (0.1%BSA) solution at 4°C. The cells were then blocked with CD16/32 
blocking antibody, followed by staining with CD45 (PE/Cy5, clone 30-F11), Ter119 
(PE/Cy5, Ter119), CD31 (PE/Cy7, clone 390) (Bio Legend, San Diego), and endomucin 
(A660, eBioV.7C7 ebioscience) antibodies and with AmCyan viability dye for 30-45 min 
at 4°C in dark. After staining, cells were washed in phosphate buffered saline (0.1% 
BSA). Stained cells were analyzed on FACSARIAIII (BD bioscience, Franklin Lanes, NJ) 
and analyzed in live (AmCyan-), non-leukemic (GFP-) CD45-Ter119-CD31+ fraction. 
Flow cytometry analysis was performed using FlowJo 10.5.3 software (FlowJo, Ashland, 
OR). 
 For measurements of Hoechst dye uptake, tLDRT-treated and abscopal femur 
and calvarium samples were crushed in phosphate buffered saline (0.1%BSA) solution. 
Cells suspensions were filtered through a 40 μm filter and centrifuged at 300xg for 5 min 
at 4°C, then incubated with ACK lysis buffer for 5-10 minutes to remove red blood cells. 
The cells were analyzed for Hoechst uptake in both the total cell and GFP+ ALL cell 





 For measurements of daunorubicin uptake, tLDRT-treated and abscopal femur 
samples were crushed in phosphate buffered saline (0.1%BSA) solution. Cells 
suspensions were filtered through a 40 μm filter and centrifuged at 300xg for 5 min at 
4°C, then incubated with ACK lysis buffer for 5-10 minutes to remove red blood cells. 
The cells were stained with AmCyan viability dye (1 µg/ml) for 15 min and washed with 
phosphate buffered saline. Cells were analyzed on AmCyan- (live) GFP+ (leukemic) cell 
population using BD FACSARIAIII sorter 2-3 hours post-harvest and were kept on ice 
throughout the staining process.  
 To monitor GFP+ ALL progression, 5-10 µL of peripheral blood was taken from 
the tail vein of mice. Samples were incubated with ACK lysis buffer for 5-10 minutes to 
remove red blood cells, then washed with phosphate buffered saline and read using the 
BD Fortessa within 24 hours. Measurements of GFP+ ALL femur engraftment were 
analyzed in similar fashion after femur samples were crushed in phosphate buffered 
saline (0.1%BSA) solution, filtered through a 40 μm filter, and centrifuged at 300xg for 5 
min at 4°C. 
2.2.7 Dextran well plate readings 
 Well plate fluorescence readings of TRITC dextran concentration were read from 
supernatants taken from crushed single-femur cell suspensions after removal of cells 
with centrifugation. Dextran femur supernatant fluorescence was measured in imaged 
mice that were euthanized 50 minutes after 150kDa TRITC dextran injection. Femurs 
were crushed in 7 ml of phosphate buffered saline (0.1%BSA) solution and centrifuged 
at 300xg for 5 minutes at 4°C. A total of 200 µl of supernatant was removed and read 
using a FilterMax F5 Multi-Mode Microplate Reader (Molecular Devices San Jose, CA). 
Well plate readings were linear over the read range (data not shown).  
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2.2.8 Statistical analysis 
 All statistical testing in this chapter was performed using Prism (V.7.01, 
GraphPad). Unless otherwise noted, significance testing between groups was performed 
using Welch’s two-sided t test with a P value<0.05 considered significant. Significance 
testing for survival data was calculated using the log-rank Mantel-Cox test. For linear 
correlation testing, R squared coefficient of determination tests were used. All 
distribution error bars are displayed as the mean plus or minus one standard error of the 
mean.  
2.3 Results 
2.3.1 Bone marrow microenvironment remodeling and leukemia 
localization during ALL growth 
 Large QMPM three-dimensional tiled images of separate mice showed steady 
progression of ALL disease burden in the calvarium from 2 to 14 days post ALL injection. 
ALL was predominately homogenously distributed throughout calvarium marrow space. 
However, occasional regions of the calvarium did contain heterogeneous pockets of ALL 
(Figure 2-1). Degradation of the calvarium was present in mice at high ALL burden 
resulting in a loss of bone-collagen second harmonic signal near the sagittal and coronal 
calvarium sutures. Additionally, X-ray CT scans revealed reduced Hounsfield Units on 
the frontal lobe of mice bearing ALL as compared to healthy control mice suggesting a 





Figure 2-1: Tiled multiphoton microscopy images of the calvarium in (A) a healthy control 
mouse and mice 2, 4, 6, 8, and 13 days post ALL injection (B-F) are shown. Red is 
Qtracker™ 655 labeled vascular blood pool fluorescence, green is GFP ALL 
fluorescence, and blue is second harmonic generation from the collagen in the bone. (G) 
GFP+ ALL fluorescent intensity in images from mouse calvarium their respective days 
post injection (one time point per mouse, n=4, 4, 4, 3, and 3 mice for each time point, 
respectively). (H) A region of heterogeneous ALL distribution. Pockets of heterogeneous 
ALL are marked with white triangles.  
 
Figure 2-2: (A, C) Three-dimensional intensity projection images of CT scans from 
healthy control mice and mice bearing ALL 12 days post ALL injection. Colored dotted 
lines indicate relative regions of multiphoton microscopy imaging performed in A and C. 
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(B, D) Multiphoton microscopy images of bone-collagen second harmonic generation are 
shown from a healthy control mouse and a mouse bearing ALL 14 days post ALL 
injection. (E) CT Hounsfield units from contoured frontal bones of healthy control mice 
and mice bearing ALL 10-11 days post ALL injection (n=5 mice per group). 
2.3.2 Changes in Ktrans and increased BMV permeability in mice bearing 
ALL 
 For all time-lapsed QMPM images, 150kDa dextran had reached the BMV 
between 6 and 12 seconds after injection.  The fluorescent time-lapsed intensity of 
150kDa dextran in the vascular ROI was well described by bi-exponential decay 
suggesting semi-consistent BMV blood flow. Dextran uptake into the extravascular 
calvarium bone marrow tissue started immediately after dextran flow into the BMV. The 
time-lapsed fluorescent intensity of dextran in blood and tissue compartments showed 
good agreement with the Toft’s compartmental model which was used for analysis 
(Figure 2-3).  
Figure 2-3: The segmentation schemas for the blood compartment and the tissue 
compartment for 150kDa TRITC dextran compartmental analysis are shown. Briefly, the 
time-lapsed images are co-registered, and Otsu’s method is used on images at an early 
time point to segment the vascular regions. To segment the tissue region, a later time 
point image is selected after dextran leakage into the tissue. The previously segmented 
vascular region is removed, and Otsu’s method is used to segment the tissue regions. 




signal in the blood and tissue compartments. Scale bars indicate the imaging window 
range for displayed early and late blood and tissue image sets. The corresponding blood 
and tissue compartment time-lapsed dextran fluorescent intensity from the segmented 
regions is displayed in linear and log scale with corresponding fitting function curves. 
  We additionally performed QMPM imaging with two smaller sized molecular 
contrast agents, 4kDa TRITC dextran and daunorubicin chemotherapy. The kinetics of 
these smaller contrast agents were compared to the kinetics of 150kDa sized dextran to 
ensure that QMPM-based, time-lapsed, imaging can be used for fluorescent agents of 
varying sizes and pharmacokinetic uptake patterns. Daunorubicin imaging was 
performed in a mouse bearing ALL. A clear distinction between vascular, tissue, and 
cellular compartments could be seen in daunorubicin images. A faster blood clearance 
and faster peak tissue uptake of daunorubicin is observed compared to dextran 
(because of its smaller molecular weight. Figure 2-4). Additionally, 4kDa dextran had a 
much faster uptake and clearance than 150kDa dextran in healthy control mice (Figure 
2-5). After ensuring that QMPM could identify changes in the kinetics of several different 
molecular contrast agents, we selected 150kDa dextran for use to measure vascular 
permeability due to its slower leakage rate. 
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Figure 2-4: QMPM images of ALL burdened mouse calvarium showing (A) Qtracker™ 
655 vascular blood pool fluorescence, (B) GFP+ ALL fluorescence, (C) the second 
harmonic generation image of the collagen in the bone, and (D) a merged image are 
shown for a daunorubicin-injected mouse. Time-lapsed imaging of daunorubicin 
fluorescence (E) before, (F) three seconds post, (G) 90 seconds post, and (H) 25 
minutes post daunorubicin injection are shown. A clear distinction between blood, tissue, 
and cellular compartments can be seen. (I) Plots of fluorescent intensity versus time for 
contoured blood, tissue, and cellular compartments are shown. (J) A representative 
image of a three-tissue compartment model applicable to daunorubicin is shown. (K) A 
comparison of fluorescent intensities of blood and tissue compartments for daunorubicin 
and 150kDa TRITC dextran in separate mice bearing ALL is shown. 
Figure 2-5: Normalized fluorescent intensity of the extravascular tissue compartment 
from time-lapsed images taken of the calvarium in healthy untreated mice using 150kDa 




uptake of 150kDa dextran occurs at approximately 6-10 minutes compared to 
approximately one minute with 4kDa dextran. 
 Validation of the compartmental model was performed by perturbing the system 
using tLDRT to the left femur and left half of the calvarium in healthy mice, as radiation 
has been shown to both increase νec (by decreasing total tissue cell number) and 
damage vasculature, causing increased leakage [51, 76, 77]. A corresponding reduction 
in total cell number in irradiated femur and calvarium bone marrow regions was found 
compared to abscopal regions. Significantly higher dextran fluorescence in crushed 
femur supernatants was found for tLDRT-treated femurs compared to abscopal femurs 
(P=0.0003), suggesting LDRT significantly increases total dextran concentration in the 
bone marrow tissue. A negative correlation between femoral bone marrow total cell 
count and dextran fluorescence of crushed femur supernatants was found, confirming 
that extracellular space and the total dextran uptake in the bone marrow are influenced 
by total cellular density (R2=0.7905, P<0.0001, Figure 2-6). 
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Figure 2-6: (A) Total number of bone marrow cells in crushed 4 Gy tLDRT-treated and 
abscopal femur samples from non-leukemic mice (n=7, 6 mice per group respectively). 
(B) Total number of calvarium bone marrow cells in crushed tLDRT-treated and
abscopal calvarium regions of non-leukemic mice with a two-sided paired t-test
calculation (n=5 mice). (C) Dextran fluorescence of crushed femur supernatants from
non-leukemic abscopal, non-leukemic 4Gy tLDRT-treated, ALL abscopal, and ALL 4Gy
tLDRT-treated single femurs (n=4, 3 non-leukemic mice and mice bearing ALL
respectively). (D) The number of total bone marrow cells in crushed single femur
samples versus dextran fluorescence of crushed femur supernatants is shown (n=15
single femurs). Abscopal and treated femurs taken from LDRT-treated non-leukemic
mice and LDRT-treated mice bearing ALL are shown. The corresponding R-squared
value and best fit line are also displayed.
 Four-Gy tLDRT significantly increased νec and Ktrans in tLDRT-treated calvarium 
regions compared to regions in untreated healthy mice (P=0.0003 and P=0.0320, 
respectively). After validation, time-lapsed QMPM images in the calvarium of mice 
bearing ALL found an increase in νec compared to healthy control mice (P=0.0172). No 




(P=0.1744), indicating that the change in νec may be due to other additional factors, such 
as bone degradation or high interstitial fluid pressure. At low-to-moderate ALL 
engraftment, Ktrans was significantly higher than healthy control mice (P=0.0488). 
Functional BMV surface area per volume in time-lapsed QMPM images decreased with 
ALL burden. A significant increase in vascular permeability was observed in mice with 
low-to-moderate ALL engraftment compared to healthy control mice (P=0.0085, Figure 
2-7 Figure 2-8).  
 
Figure 2-7: (A) TRITC dextran fluorescence is shown for a healthy mouse and a mouse 
bearing ALL immediately and ten minutes after dextran injection is shown in gray. 
Merged images verifying the local presence of ALL are shown. Green is GFP+ ALL 
fluorescence, red is TRITC dextran fluorescence, and blue is bone-collagen second 
harmonic generation. (B) Time-lapsed dextran fluorescent intensity from segmented 
tissue compartment regions is plotted with corresponding fitted tissue compartment 
curves for the control mouse and mouse bearing ALL shown in A. The vertical striped 
line indicates the 10 minutes post injection time point depicted in the images. (C) A plot 
of time-lapsed dextran fluorescent intensities from the segmented tissue compartments  
of a healthy control mouse, a non-leukemic 4 Gy tLDRT-treated mouse, a mouse with 
8% ALL femoral bone marrow engraftment, and a mouse with 58% ALL femoral bone 
marrow engraftment. The fitted tissue compartment curves for each mouse are also 
plotted. 
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Figure 2-8: (A) Values for νec are shown for healthy control mice, non-leukemic LDRT-
treated mice, and mice bearing ALL (n=5, 4, 8 mice per group respectively). (B, E) 
Values for Ktrans and vascular permeability are shown for healthy control mice, non-
leukemic tLDRT-treated mice, mice with less than 40% ALL femoral bone marrow 
engraftment, and mice with more than 55% ALL femoral bone marrow engraftment. 
(n=5, 4, 5, 3 mice respectively). (D) Vessel surface area versus GFP+ ALL femur bone 
marrow engraftment with the corresponding R-squared value and best fit line are plotted 
for untreated mice analyzed with QMPM compartmental modeling (n=13 mice). (C, F) 
Plots of ALL femur bone marrow engraftment compared to Ktrans and permeability for 
healthy control mice and mice bearing ALL is shown (n=13 mice). 
2.3.3 BMV remodeling results in angiogenesis, poor blood flow, and loss 
of functional vessels with ALL 
 Crushed femur and tibia samples were analyzed by flow cytometry to observe 
endothelial cell changes with ALL progression. An increase in the CD45/TER119- 
CD31+ endothelial cell fraction in total live cells was observed in mice bearing ALL 
compared to control mice (P=0.0032). No significant differences in femoral bone marrow 




suggesting an overall increase in the total number of endothelial cells present in the 
bone marrow of mice bearing ALL (P=0.1744). Additionally, a significant reduction in the 
high endomucin expressing endothelial cell fraction in total endothelial cells was found 
for mice bearing ALL compared to control mice (P<0.0001, Figure 2-9). High endomucin 
expressing endothelial cells have previously been reported to co-localize with osteoblast 
progenitors in the growth plate regions of the femoral bone and are responsible for 
hematopoietic stem cell (HSC) maintenance by secreting HSC-supporting cytokines [78]. 
These data suggest that ALL transforms the endothelial subset away from a 
hematopoietic supporting niche in support of ALL.  
 
Figure 2-9: (A) Flow cytometry analysis of the percentage of CD31+ endothelial cells in 
total live cells for control, 8 days, and 13-14 days post ALL injection are shown (n=10,5,9 
mice per group respectively). (B) The fraction of high endomucin-expressing endothelial 
cells in total endothelial cells for control, 8 days post ALL injection, and 13-14 days post 
ALL injection mice is shown (n=10,5,9 mice per group respectively). (C) Corresponding 
GFP+ ALL engraftment for mice analyzed for endothelial cell flow cytometry analysis in 
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subfigures A & B (n=5, 9 mice per group respectively).(D) The flow cytometry gating 
scheme for CD45Ter119- CD31+ endothelial cell population and high endomucin 
subpopulation is shown. 
 Endothelial expansion was accompanied by large changes in BMV function and 
morphology. QMPM measurements of calvarium mean vessel density were higher in 
mice bearing ALL compared to those in healthy control mice (319 mm-2, P= 0.0017).  
QMPM revealed a significant reduction (8.93 μm) in the average inner diameter of 
vessels in the calvarium in mice bearing ALL compared to healthy control mice 
(P<0.0001, Figure 2-10).  
Figure 2-10: Representative tiled maximum intensity projection images of Qtracker™ 
655 vascular blood pool fluorescence for (A) control mice and mice (B) 4 days, (C) 8 
days, and (D) 13 days post ALL injection are shown. Measurements of (E) mean vessel 
density and (F) vessel diameter from images of healthy control mice and BCR-ABL mice 




 Average velocities of cells flowing through the BMV of mice bearing ALL 
(1.34±0.11 mm/s) were reduced compared to healthy control mice (3.70 ± 0.484 mm/s, 
P<0.0001). Control mice typically had small inner diameter vessels with rapid blood flow 
connected to slow flowing vessels with a large inner diameter. Alternatively, mice with 
moderate-to-high ALL burden displayed a more homogenous population of vessels in 
terms of both blood flow velocity and vessel diameter, suggesting that typical cellular 





Figure 2-11: Merged color images of the calvarium of (A) mice bearing ALL and (C) 
control mice. Green is GFP+ ALL fluorescence, red is Qtracker™ 655 blood pool 
fluorescence, and blue is the second harmonic generation of collagen in the bone. 
Vascular blood pool images with corresponding blood velocity mapping of upstream to 
downstream vessels labeled 1-11 are displayed for (B) ALL burdened vessels and (D) 
healthy vessels. Mice bearing ALL were imaged 8 days post ALL injection. (E) 
Intravascular cellular velocity and (F) vessel diameter measurements from labeled 
vessels in B and D show the loss of upstream, fast-flow, small-diameter vessels and 
downstream, large-diameter, slow-flow vessels in mice bearing ALL. Plots of cell velocity 
versus diameter for (G) ALL burdened vessels eight days post ALL injection and (H) 
healthy control vessels (n=3 mice per group, 10 vessel measurements per mouse).  
 QMPM imaging revealed regions of semi-collapsed vessels in the calvarium of 
mice as early as day 8 post ALL injection. Accumulation of non-moving cells in blood 
vessels was observed near regions of partial BMV collapse. The BMV opened and 
closed intermittently in some mice bearing ALL during time-lapsed imaging, but not in 
control mice (Figure 2-12). Measurements of systolic and diastolic pressure were taken 
to better understand the mechanics behind BMV closing. Reductions in systolic (56.2 
mm Hg) and diastolic pressure (31.0 mm Hg) were measured with the onset of ALL 
(P=0.0002 and 0.0375, respectively, Figure 2-13), suggesting that reduced systemic 
blood pressure may contribute to BMV collapse.  
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Figure 2-12: Tiled QMPM images of Qtracker™ 655 vascular blood pool fluorescence in 
the calvarium of ALL-transplanted mice at (A) 8 days and (B) 14 days post ALL injection. 
Red dashed lines indicate regions of vascular collapse. (C) Merged composite images of 
Qtracker™ 655 blood pool fluorescence (gray), GFP+ ALL fluorescence (green), and the 
second harmonic generation image of the collagen in the bone (blue) for ALL injected 
mice 8 days post injection. Red triangles and red dashed lines indicate specific vessel 
collapse and regions of vascular collapse, respectively. Yellow dashed lines indicate 





Figure 2-13: (A) A normalized plot of mouse pulse rate, diastolic blood pressure, and 
systolic blood pressure before ALL injection and 3, 5, 7, 12, and 14 days following ALL 
injection. (B-D) Plots of systolic blood pressure, diastolic blood pressure, and pulse rate 
in mice before and 14 days after receiving ALL injection with two-sided paired t-test 
significance values.  
 
2.3.4  LDRT improves blood flow, improves chemotherapy delivery, and 
increases survival in combination therapy 
 Next the effects of LDRT on the BMV in mice bearing ALL were tested with the 
hypothesis that LDRT would be beneficial to 1) improve the function and morphology of 
the BMV, 2) enhance therapeutic uptake, and 3) increase treatment efficacy when used 
prior to the administration of therapeutics. tLDRT treatments altered the morphology and 
function of the BMV in mice bearing ALL two days post treatment. Two-Gy tLDRT 
treated mice bearing ALL had increased average vascular diameter (13.4 µm) and 
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increases in the average velocity of cells flowing through the BMV network (2.41 mm/s) 
compared to untreated mice bearing ALL (P< 0.0001 and 0.0001, respectively). These 
treatments increased average cellular vascular velocity to similar levels as in healthy 
control mice (P=0.9497). Similar BMV changes were observed with 2 Gy TBI treatments, 
suggesting that systemic LDRT to the cardiovascular system does not largely impact 
blood flow, and that functional vascular changes may be beneficial for a variety of 
systemic or targeted RT treatments (Figure 2-14).  
Figure 2-14: Tiled images taken two days post 4 Gy tLDRT and 13 days post ALL 




Qtracker™ 655 vascular blood pool fluorescence in red, (B) GFP+ ALL fluorescence in 
green, and (C) a merged image with bone-collagen second harmonic generation in blue. 
(D) A representative three-dimensional intensity projection CT image depicting the 
tLDRT treatment region. (E) CT images with isodose lines showing the corresponding 
4Gy tLDRT irradiated calvarium region shown in A-C. (F-H) Intravascular cellular velocity 
and vessel diameter plots for individual blood vessels are plotted for healthy control 
mice, non-treated mice bearing ALL, 2 Gy tLDRT-treated healthy mice, 2 Gy tLDRT-
treated mice bearing ALL, and 2 Gy TBI-treated mice bearing ALL (n=3 mice per group). 
Ten individual vessel measurements were taken from each mouse. Untreated and 
irradiated mice bearing ALL were imaged 8 days and 9 days post-ALL injection, 
respectively.  
 After seeing changes in the BMV with tLDRT and TBI, the therapeutic delivery of 
Hoechst and daunorubicin to the bone marrow was measured by cellular uptake using 
flow cytometry. Mice were administered intravenous injections of Hoechst or 
daunorubicin two days after 2Gy and 4Gy tLDRT and 20 minutes before euthanizing 
mice for tissue harvest. To observe changes in drug uptake, tLDRT-treated calvarium 
and femur regions were compared to matching abscopal regions in mice bearing ALL. 
The percentage of total cells stained positive for Hoechst in abscopal calvarium regions 
had a negative correlation with ALL engraftment, whereas no significant changes in 
overall total cell number were seen in the femoral bone marrow of mice bearing ALL 
compared to healthy mice (P=0.1744). This suggests that cellular Hoechst uptake is 
inhibited by the onset of ALL but not reduced due to a change in total cell number. Non-
leukemic tLDRT-treated mice showed high percentages of total calvarium marrow cells 
labeled positive for Hoechst in both 2 Gy tLDRT-treated (94.7 ± 3.9%) and abscopal 
calvarium regions (90.5 ± 1.0%, Figure 2-15).  
  In 2Gy tLDRT-treated regions compared to abscopal regions, increases in the 
percentage of ALL cells labeled positive for Hoechst (88.3±3.6% and 63.5±3.0% 
respectively, P=0.0067) and daunorubicin (90.8±2.3% and 72.3±1.8% respectively, 
P=0.0036) were found (Table 2-1). Similar trends were observed with 4 Gy tLDRT 
treatments. QMPM-based image segmentation of ALL cells revealed higher 
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daunorubicin fluorescence for cells in 2 Gy tLDRT-treated calvarium compared to 
abscopal calvarium (P=0.0362, Figure 2-16). Results demonstrate enhanced cellular 
uptake of small molecular weight therapeutics after neo-adjuvant LDRT. 
Figure 2-15: (A) A representative gating scheme for Hoechst+ GFP+ and Hoechst- 
GFP+ ALL populations. (B) Flow cytometry analysis of the percentage of total cells 
stained positive for Hoechst versus the percentage of cells in the abscopal calvarium 
that are GFP+ ALL (n=13 mice). The corresponding R-squared value and non-zero 
significance value are shown. (C) A plot of the percentage of total cells labeled positive 
for Hoechst dye in 2 Gy tLDRT-treated, 4Gy tLDRT-treated and corresponding abscopal 
calvarium regions for non-leukemic mice (n=2 mice per group, one abscopal and one 






Table 2-1: ALL cellular uptake of Hoechst Dye and Daunorubicin 
* Indicates Welch 2-sided t test value of P < .05 when comparing matching abscopal and 
targeted tissue regions. 
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Figure 2-16: (A) QMPM images of treated and abscopal calvarium regions for a mouse 
receiving 2 Gy tLDRT. Qtracker™ 655 vascular blood pool fluorescence is in gray, GFP 
ALL fluorescence is in green, daunorubicin fluorescence is in red, and bone-collagen 
second harmonic generation displayed in the merged image is in blue. Daunorubicin was 
injected 20 minutes prior to imaging. (B) Cellular daunorubicin fluorescence taken from 
image segmentation of 30 single ALL cells with the highest GFP fluorescent intensity for 
2 Gy tLDRT-treated and abscopal regions shown in A. (C) Representative histograms of 
daunorubicin fluorescence from ALL cells from crushed femur bone marrow samples. 
 To test the treatment efficacy of the therapeutic delivery enhancements after 
neo-adjuvant LDRT, we treated mice with 4 Gy TBI in combination with nilotinib. TBI was 
chosen for treatment since it had similar effects on the BMV as tLDRT and it was more 
suitable as a treatment regimen. Four-Gy dose was chosen because it exhibits 
increased cell killing effects compared to 2Gy with similar enhancements in therapeutic 




TBI, 4Gy TBI after nilotinib, and 4 Gy TBI before nilotinib treatment groups. Significantly 
increased percentages of ALL in the peripheral blood were found in mice treated with 
4Gy TBI after nilotinib compared with mice treated with 4 Gy TBI before nilotinib at both 
15 days (22.3%, P=0.031) and 17 days (36.5%, P=0.0086) after the start of treatment. A 
significant increase of 8.5 days in median survival was found when administering 4 Gy 
TBI before nilotinib compared to 4 Gy TBI after nilotinib (P=0.0036). Results show a 
substantial survival benefit when performing 4 Gy TBI before administering nilotinib 
(Figure 2-17). 
 
Figure 2-17: (A) A treatment schema for mice bearing ALL is shown for untreated, 
nilotinib , 4 Gy TBI, nilotinib before  4 Gy TBI, and 4 Gy TBI before nilotinib treatment 
groups. Treatment was started at day 7, when ALL could be detected in the peripheral 
blood of all the mice. (B) A plot of the percentage of ALL in peripheral blood for 
untreated (n=4, 5, 5, 5 mice per time point for days 5, 6, 7, 11 respectively), 4Gy TBI 
after nilotinib (n=6 mice per time point), and 4 Gy TBI before nilotinib (n=6, 6, 6, 4, 6 
mice per time point for days 5, 6, 7, 15, 17 respectively) treatment groups (*=p<0.05, 
**=p<0.01).The gray shaded box indicates days 7-10 when treatment was administered. 
(C) The survival plot for mice bearing ALL receiving no treatment, nilotinib only, 4 Gy TBI 
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only, 4Gy TBI after nilotinib, and 4 Gy TBI before nilotinib is shown (n=5, 5, 5, 6, 6 mice 
per group respectively). Significant differences in survival are seen between all 
treatments except nilotinib only and 4 Gy TBI only treatments (*=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001). 
2.4 Discussion 
 In this study, compartmental modeling and multiphoton microscopy were 
combined to create QMPM, a single-platform method to both measure BMV functional 
characteristics and assess the pharmacokinetics of fluorescent therapeutic analogues. 
Assessments of mice bearing ALL revealed increased permeability, altered Ktrans, 
increased νec, reduced vascular blood flow, increased mean vessel density, and reduced 
mean vessel diameter. ALL-induced alterations reduce cellular drug uptake of 
therapeutics. As hypothesized, LDRT increased BMV blood flow and enhanced 
therapeutic delivery to ALL cells in the bone marrow. Consequently, 4 Gy TBI prior to the 
administration of nilotinib significantly increased the survival of mice bearing ALL 
compared to treatment with TBI after nilotinib administration. These results demonstrate 
the ability of QMPM to characterize and optimize the malignant vasculature for 
combination therapy. 
 QMPM can model the transport of therapeutic analogues in the local tissue and 
vascular compartments to obtain Ktrans and νec. Changes in the vascular transport of 
molecular agents occur early in the progression of malignant disease, making νec and 
Ktrans useful as potential biomarkers and for assessing drug or oxygen delivery [43, 79]. 
Limited work has been done with microscopy to perform tissue compartmental modeling 
for the identification of vascular permeability [47, 57]. Moreover, to our knowledge there 
have been no successful attempts using time-lapsed microscopy data to perform 
compartment modeling and obtain both Ktrans and νec for the local vasculature. 




be present in poorly perfused tissues [48, 80]. In such a case, QMPM images of the local 
vasculature will represent the local tracer transport rather than the typical transport from 
arterial blood to whole tissue. However, in the case of well perfused tissue, as is likely in 
this work, arterial and local vascular blood concentration measurements will be relatively 
similar. QMPM can be used in many different tissue types with many fluorescent agents, 
making it applicable to a wide variety of biological applications such as delivery of 
nutrients, oxygen, and therapeutics.  
  At low to moderate leukemic burden, dextran-based Ktrans is increased compared 
to that in healthy mice, likely because of increased BMV permeability, enabling faster 
dextran leakage through the endothelial wall. Increased Ktrans values in low to moderate 
burden ALL may indicate a therapeutic window of enhanced delivery for ALL antibody 
therapies, such as those targeting CD19 or CD22, which are similar in size to 150KDa 
dextran [81, 82]. However, differences in vascular transport mechanisms of dextran and 
therapeutic antibodies make further assessments of antibody delivery kinetics necessary 
[83]. In contrast to 150kDa dextran, small molecular agents such as Hoechst and 
daunorubicin can easily cross the vessel wall of both healthy and ALL-burdened BMV. 
This results in decreased cellular uptake of small sized therapeutics with the onset of 
ALL, due in part to reduced blood flow.  
 Previous reports have shown arterial and sinusoidal blood vessels to be linked 
with phenotypes observed in healthy mice. Small diameter, fast flow BMV correlates with 
arterial vessels, whereas large diameter, slow flow BMV correlates with sinusoidal 
vessels and venules for healthy mice [56, 57]. With ALL vascular remodeling, the 
structure of the healthy BMV is lost because of unchecked angiogenesis, creating semi-
collapsed, immature, permeable vessels. This results in poor delivery of therapeutic 
agents, oxygen, and nutrients through the BMV. Increased hypoxia in the bone marrow 
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has been reported with multiple hematological malignancies and is likely due to similar 
vascular alterations as reported in this work [34]. Additionally, early preservation of the 
healthy BMV by the inhibition of vascular remodeling in vivo has been shown to give a 
survival advantage for leukemic mice treated with chemotherapy, suggesting drug 
delivery is hampered by the onset of malignancy [8]. A restoration of BMV blood flow 
and reduction of high disease burden are crucial to improve the delivery of therapeutics 
to the bone marrow.  
 This study suggests a possible new role for LDRT in restoring the biophysical 
function of the malignant BMV for combination therapies. Neo-adjuvant, LDRT 
treatments to ALL-burdened mice enhance BMV blood flow, increase delivery of 
therapeutics, and improve treatment efficacy. Similar RT-induced vascular alterations in 
solid tumors have been reported and may stem from nitrous oxide-dependent 
vasodilation [31]. Our results demonstrate the ability of LDRT to actively alter the BMV 
and indicate a possible new treatment approach for hematological malignancies. While 
recently developed total marrow irradiation is capable of delivering highly conformal 
treatment to the bone marrow [40, 84, 85] or to smaller regions of high disease burden, it 
is often used in conjunction with high dose regimens to enhance cell killing [86]. In 
contrast, LDRT can provide both cell killing and vascular modulation to enhance 
therapeutic delivery in desired regions. 
 With the wide variety of therapeutics that can be used with LDRT, consideration 
should be given to select synergistic treatment approaches. LDRT treatments may be 
particularly effective for vasculature targeting therapeutics, where delivery depends only 
on vascular blood flow to endothelial cells. Vascular disrupting agents frequently illicit 
off-target toxicity [87], and therapies designed for vascular normalization frequently lead 




targeted therapeutics show synergistic effects following low-to moderate-dose RT in 
solid tumor models, allowing for reduction in drug delivery without compromising 
treatment efficacy [90]. Immunotherapy has also shown synergy with LDRT in solid 
tumor models [91]. Additionally, LDRT for hematopoietic malignancies can be explored 
with more traditional therapeutic agents that elicit off-target toxicity or have synergistic 
effects [92, 93]. 
2.5 Conclusion 
 In conclusion, LDRT-induced alterations to functional BMV characteristics are 
one example of the many possible applications for QMPM. Simultaneous measurements 
of both functional single-vessel BMV characteristics and therapeutic pharmacokinetics 
using QMPM can observe and optimize oxygen, nutrient, and drug transport for many 
disease models and tissues. In the context of ALL, such measurements are crucial to 
understand LDRT treatment-induced BMV alterations and their effects on treatment 
outcome. Future work exploring LDRT will investigate the effects of timing, dose, and 
dose fractionation on the treatment of hematological malignancies. QMPM 
measurements will be essential to observe the BMV for LDRT-based combination 
therapies. 
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Chapter 3: L-QMPM to directly assess drug 
delivery potential of the bone marrow 
vasculature 
This chapter is based largely on a manuscript that has been submitted to the 
international journal of radiation oncology, biology physics for publication in February 
2021, by Brooks J, Zuro D, Song J, Madabushi S, Sanchez J, Kortylewski M, Chen B, 
Gupta K, Storme G, Froelich J, Hui S titled "Longitudinal preclinical imaging 
characterization of drug delivery potential after radiotherapy in the healthy and leukemic 
bone marrow vascular microenvironment”. It is available for viewing in pre-print at: 
https://doi.org/10.1101/2021.02.23.432514 
3.1 Introduction 
 In chapter 2, QMPM was used to discover that low dose (2-4 Gy) RT increases 
single-vessel blood flow in mice bearing ALL [94]. Increases in blood flow coincided with 
increased cellular uptake of chemotherapy, as well as improved survival outcome for 
mice treated with chemotherapy after neo-adjuvant low-dose radiotherapy. However, the 
correlation between improved BMV blood flow and improved cellular uptake of 
chemotherapy does not assure increased drug delivery potential after RT. Additional 
factors influence cellular uptake of therapeutics, such as tissue cellularity and the affinity 
of cells to uptake chemotherapy [95]. Furthermore, measurements of cellular drug 




observe longitudinal changes required for sustained drug delivery. Therefore, 
longitudinal measurements of drug delivery potential would be beneficial to assess the 
effectiveness of RT in conditioning the BMV for chemotherapy delivery.  
 In this chapter we develop longitudinal quantitative multiphoton microscopy (L-
QMPM) to, 1) directly assess the drug delivery potential of the BMV after RT, 2) quantify 
potential time-lapsed imaging-based disease biomarkers, and 3) better understand the 
relationship between underlying vascular alterations and measurements obtained from 
DCE imaging. We quantified drug delivery potential primarily as the extravascular tissue 
wash-in slope (WIStissue) calculated using time-lapsed imaging of 4kDa dextran. 4kDa 
sized dextran was chosen as it is similar in size to typical DCE MRI imaging contrast 
agents as well as most standard chemotherapies for leukemia and has a minimal effect 
on the bone marrow microenvironment [60]. We measured several additional time-
lapsed imaging and microvascular parameters, including Ktrans and single-vessel blood 
flow to understand how the BMV influences changes in DCE imaging parameters and 
WIStissue. We performed L-QMPM imaging in the calvarium of mice bearing ALL or AML, 
two common types of leukemia, as well as wild-type (WT) controls, to assess the 
response of the healthy and leukemic BMV to RT. We hypothesized that RT would 
increase WIStissue in the calvarium bone marrow of mice bearing leukemia after both low 
(2 Gy) and high (10 Gy) dose total body irradiation (TBI).  
3.2 Methods 
3.2.1 Mice, cell lines, and study timing 
  All procedures for animal experimentation were performed according to City of 
Hope’s guidelines and approved by the Institutional Animal Care and Use 
Committee. For all imaging studies, male and female C57BL/6 WT mice (Strain 556, 
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Charles River, Wilmington MA USA) 7-11 weeks in age were used. Mice were injected 
with 1x106 green fluorescent protein (GFP)+ BCR-ABL (p190Kd) expressing B-cell ALL 
cells [66] or 1x106 GFP+ Cbfb-MYH11/Mpl+ AML cells [96]. The percentage of leukemia 
in peripheral blood (PB) and in bone samples was measured by flow cytometry as 
described previously [94].  
 For initial non-imaging studies of ALL growth kinetics, 6-week-old C57BL/6N mice 
(Strain 556, Charles River, Wilmington, MA) were used. Initial growth kinetic studies of 
AML were performed with 9-week-old male and female albino B6 mice (B6 Tyrc-2J/J-B6 
stock No: 000058, Jackson Laboratories, Bar Harbor, ME). For ALL and AML cell 
injections, cells were suspended in 200 µl or 100 µl of phosphate buffered saline (PBS) 
respectively. ALL and AML injections were administered using tail vein or retro-orbital 
injections respectively. 
 Surgery on WT mice was performed 2 days before the start of imaging. ALL 
injections and headplate surgery on mice bearing ALL were performed 7-8 days and 2-3 
before the start of imaging respectively. ALL was detectable in the peripheral blood (PB) 
of all sampled mice at the first imaging timepoint with PB readings ranging from 0.5% to 
12.9%. Approximately 75% of the mice bearing ALL were sampled. An additional group 
of mice bearing ALL were treated with 10Gy at higher burden. ALL injections and 
headplate surgery for these mice was performed 10 and 2 days before the start of 
imaging respectively. PB readings of these mice at the start of imaging ranged from 32% 
to 55% for all mice. Headplate surgery on mice bearing AML was performed after mice 
reached 25% AML cells in PB. AML injections and headplate surgery were performed 
10-16 and 2 days before the start of imaging, respectively. AML in the PB at the start of




treatment group for healthy and leukemic mice consisted of a minimum of two mice of 
each sex. 
 
Figure 3-1: The timing schema for ALL or AML intravenous injection, cranial window 
surgery, TBI, and L-QMPM imaging is shown. 
3.2.2 Cranial window surgery 
  Two days before surgery mice were given MediGel® Sucralose gel cups 
(Clear H2O, Portland, ME) mixed with 1.125 mg of carprofen per cup. An additional cup 
was given on the day of surgery. For surgery, mice were anesthetized using 5% 
isoflurane initially at a flow rate of 1.0 L/min, and then maintained with 1.3% isoflurane at 
a flow rate of 0.8 liters per minute. A stereotactic apparatus with a bite bar was utilized to 
keep the mouse stable during surgery. The hair on the top of the skull was removed 
using a hair trimmer and the skin above the skull was sterilized using a topical antiseptic 
(Betadine®, Purdue Products L.P., Stamford, CT), and rinsed with saline. An incision 
was made to remove the skin and membrane above the calvarium, and a custom head 
plates made of carbon fiber or titanium with an inner diameter of 7mm or 8mm 
respectively was fixed to the calvarium using glass ionomer cement (Pearson PQ, 
Sylmar, CA). A round 5mm glass coverslip was placed on top of the exposed skull in the 
middle of the headplate, and was sealed with cyanoacrylate glue (Loctite 401™, Henkel, 
Düsseldorf, Germany). Mice were administered 0.5-1.0 mg/kg of buprenorphene-SR 
(ZooPharm, Fort Collins, CO) as an additional analgesic at the time of surgery.  
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3.2.3 L-QMPM image acquisition and analysis 
 For imaging, mice were anesthetized using 5% isoflurane initially at a flow rate of 
1.5 L/min, and then maintained with 1.3% isoflurane at a flow rate of 0.8 liter per minute. 
The stereotactic head plate was inserted into a custom-built heated stage maintained at 
37°C allowing for easy viewing of the mouse calvarium. Imaging was performed on the 
frontal bone region of the calvarium, near the sagittal suture for all mice, using the same 
system as described in section 1378065747.745753680.978588032.  
 Mice were catheterized intravenously through the tail vein [61] and injected with 
350 µg of 4kDa TRITC dextran (TdB Consultancy, Uppsala Sweden) suspended in 100 
µl of phosphate buffered saline (PBS) during time-lapsed imaging to observe drug 
delivery potential. Time-lapsed imaging consisted of 120 frames with 10.3 second frame 
interval at a 512 by 512 pixel resolution.  
 To identify the vascular region from the tissue region, a second injection of either 
400 µg of 2MDa FITC dextran (TdB Consultancy, Uppsala Sweden) suspended in 100 µl 
of PBS or 10µl of Qtracker™ 655 Vascular Label mixed with 90 µl of PBS was 
performed after time-lapsed imaging. Immediately after injection, a series of fast, five-
slice z-stack images with 15 µm spacing, 512 by 512 pixel resolution, and no averaging 
were taken from 5 locations before tissue leakage of FITC dextran or Qtracker™ 
occurred. Substantial leakage was often present in mice treated with TBI due to loss in 
cellularity and vascular damage. This made clear viewing vascular morphology difficult 
after the first 2-3 minutes in most irradiated mice. Three-dimensional tiled z-stack 
images of ALL and blood pool fluorescent contrast were obtained with settings of 10um 
slice spacing, 512 by 512 pixel resolution, two averages and individual image overlap of 




excitation, GFP+ leukemia excitation, and second harmonic generation of the collagen in 
the bone was performed at 900nm. 
 Three separate fast z-stack images were used to manually measure mean vessel 
density and mean vessel diameter for each mouse using Fiji/ImageJ [68]. Measurements 
of corrected single-vessel blood flow were acquired using Equations 1-5 & 1-6 [2]. Tiled 
z-stack images were stitched together using a Fiji/ImageJ plugin [70]. 
 To identify the vascular tissue ROI, an Otsu’s threshold [71] was applied to blood 
pool agent images of the vasculature. To identify the extravascular tissue ROI, the 
vascular tissue ROI was cropped out of the 4kDa dextran image and an Otsu’s threshold 
was applied to the 15th frame of the dextran time-lapsed images. If a single threshold 
was not adequate to properly segment the extravascular tissue ROI from the 
background, the first extravascular ROI region was subtracted from the image and a 
second Otsu’s threshold was applied. The two extravascular tissue regions were then 
combined to identify the extravascular tissue ROI. Two thresholds were only applied in a 
few cases where there was extensive heterogeneity in tissue signal intensity in the 
image. The whole tissue ROI was identified by combining extravascular and vascular 
ROIs. After identifying initial ROIs, boundary edge erosion was applied to the regions to 
better isolate dextran fluorescent signal coming from the respective tissue 
compartments. An 8 pixel boundary erosion was applied to extravascular and whole 
tissue ROIs. A 4 pixel boundary erosion was applied to the vascular tissue ROI.  
 Time-lapsed imaging of 4kDa TRITC dextran were analyzed using a custom 
Matlab® (R2018a 9.41.0.81364, MathWorks Natick, MA) script obtaining compartmental 
modeling parameters and descriptive curve analysis of dextran uptake. Images frames 
were co-registered to minimize spatial drift between frames of time-lapsed images. For 
calculation of Ktrans, Kep, and νec removal of saturated pixels from extravascular and 
61 
vascular ROI’s was performed prior to analysis. To do this, the percentage of saturated 
pixels from the ROI with the highest percentage of saturated pixels was identified, and 
that percentage of pixels was removed from both the vascular and extravascular ROIs. 
Saturated pixels were only present for a subset of the total images, and in general the 
removal of saturated pixels made little change to the overall signal intensity from ROIs. 
The concentration of dextran in the vascular and extravascular tissue ROI was modeled 
using Equation 1-3. 
 Analysis of the extravascular tissue ROI signal contributions to PHwhole was 





 Where SItissue and SIblood are the mean fluorescent intensities from the 
extravascular and vascular tissue ROIs after boundary erosion is performed at the time 
that PHwhole is measured. Atissue and Ablood are the areas covered by the extravascular and 
vascular tissue ROIs before boundary erosion is performed.  
 The additional parameters of dextran accumulation that we quantified included 
WIStissue , wash-in slope for the whole tissue ROI (WISwhole), peak height for the 
extravascular tissue ROI (PHtissue ), peak height for the whole tissue ROI (PHwhole ), and 
peak height for the vascular tissue ROI (PHblood). WISwhole and PHwhole were quantified as 
measurements similar to macroscopic DCE imaging to identify how signal contributions 
from the vascular and extravascular tissue influence DCE imaging (Figure 3-2) [47]. 
 We obtained WIStissue and WISwhole by dividing the largest positive change in 
fluorescent intensity between each frame by the time interval between frames for the 
ROIs of the extravascular and whole tissues, respectively. PHblood, PHtissue, and PHwhole 
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were calculated by first subtracting the pre-injection background fluorescence from time-
lapsed images, then measuring the dextran fluorescent intensity value of the frame with 
the highest fluorescent intensity for vascular, extravascular, and whole tissue ROIs, 
respectively [42]. 
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Figure 3-2: (A) Fluorescent intensity data from extravascular tissue, vascular tissue, and 
whole tissue ROIs from time-lapsed L-QMPM images shown to graphically illustrate 
measurements. Solid lines represent fitted functions for the vascular and extravascular 
tissue compartments used to obtain Ktrans, Kep, and νec. WIStissue and WISwhole are depicted 
as the maximum positive slope between image frames for the extravascular tissue ROI 
and whole tissue ROI, respectively. (B) The list provides a description of the parameters 
of interest for Chapter 3 and the relation of the parameters to physiological parameters 




3.2.4 TBI treatments, head plate dosimetry, and dose simulations 
 We used the Precision X-RAD SMART Plus / 225cx small animal image guided 
irradiation system[72] to administer TBI treatments in a single-fraction of a 2 or 10 Gy 
soft-tissue-equivalent dose, acquire CT images, and perform dose calculations [73, 74]. 
TBI treatments were performed while mice were conscious with x-ray tube settings of 
225 kVp and 13 mA with a 0.32 mm copper filter. CT imaging was performed on mice 
under anesthesia (2% isoflurane at a flow rate of 1.5 liters per minute) with x-ray tube 
settings of 40 kVp and 13 mA at a 0.2 mm voxel size with a 2.0 mm aluminum filter. Film 
dosimetry was performed using GafchromicTM EBT3 film (Ashland Specialty Ingredients, 
Bridgewater NJ). The film was initially calibrated at the isocenter of the system after 
verification of the dose with an externally calibrated ion chamber (PTW TN30013 Farmer 
Chamber, Freiburg, Germany). An output dose of approximately 1.5 Gy was chosen for 
headplate dosimetry as it was the dose in the center of the linear response of the film 
(data not shown). Dose calculations and isodose line visualization were performed by 
the small animal RT planning system [72], using a Monte Carlo dose engine [73, 74]. 
3.2.5 Histology preparation and scoring 
 After completion of imaging 5 days after RT, bone tissues were dissected and 
fixed in 10% neutral buffered formalin for 48 hours. Bone tissues were decalcified using 
Richard-Allan Scientific™ Decalcifying Solution (Thermo Scientific™) with 6 hours 
incubation and raised. Dehydration, clear, and paraffinization was performed on a Tissue 
-Tek VIP Vacuum Infiltration Processor (Sakura Finatek, Torrence, CA, USA). The 
samples were then embedded in paraffin using a Tissue-Tek TEC Tissue Embedding 
Station (Sakura Finatek), cut at 5 μm and stained with a Tissue -Tek Prism Plus 
automated H&E Stainer (Sakura Finatek) according to standard laboratory procedures. 
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 Dual IHC stain for CD31 (Clone: D8V9E Rabbit monoclonal antibody, Cell 
Signaling Technologies, Danvers, MA, USA) and GFP (Clone: D5.1 Rabbit monoclonal 
antibody, Cell Signaling Technologies, Danvers, MA) was performed on Ventana 
Discovery Ultra automated IHC stainer (Ventana Medical Systems, Roche Diagnostics, 
Indianapolis, USA). Briefly, after deparaffinization, rehydration, endogenous peroxidase 
activity inhibition and antigen retrieval, the two antigens were sequentially detected, and 
heat inactivation was performed to prevent antibody cross-reactivity between the same 
species. Following each primary antibody incubation, DISCOVERY anti-Rabbit HQ and 
DISCOVERY anti-HQ-HRP were incubated. The stains were then visualized with 
DISCOVERY Teal kit and DISCOVERY Purple Kit, respectively, counterstained with 
haematoxylin (Ventana), and coverslipped. Whole slide images were acquired with a 
Ventana iScan HT Scanner (Roche Diagnostics, Indianapolis, IN, USA) and viewed by 
iScan image viewer software. Histological vessel density scoring was performed 
manually using femur sections stained for CD31 to identify endothelial cells. Two 
separate images were quantified for vessel density per mouse. All pathological findings 
were verified by a board-certified pathologist with expertise in bone marrow pathology 
(Joo Y Song MD, City of Hope National Medical Center). 
3.2.6 Statistical analysis 
We performed all statistical testing using Prism (V.9.00 (121), GraphPad). For 
analysis of the treatment effects, a two-way mixed-effects model was performed followed 
by Tukey’s post-hoc comparison when appropriate. We performed post-hoc 
comparisons with 3 families and 3 comparisons per family for both time and treatment 
group comparisons. Measurements of leukemia in the PB of mice in treatment groups 
were compared using a one-way mixed-effect model for cross group and longitudinal 




a Welch’s two-sided t-test. All distribution error bars are displayed as the mean plus or 
minus one standard deviation.  
3.3 Results 
3.3.1 Head plate dosimetry 
 Dosimetry measurements and CT-based dose simulations were performed to 
ensure minimal perturbation in dose due to cranial window surgery and implantation of 
the cranial window headplate. Significant differences in dose were noticed between a 
lack of head plate and directly under the titanium head plate material, whereas no 
significant differences were noticed between a lack of head plate and carbon fiber 
headplates (Figure 3-3). 
 
Figure 3-3: A picture of dosimetric film after x-ray exposure while directly underneath a 
titanium head plate. Film dose measurements from a lack of head plate, carbon fiber 
head plates, and titanium head plates obtained both underneath the head plate (Green) 
material and in the imaging area (Red). 
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 We observed significant artifacts in CT images of mice with titanium head plates. 
However, no artifacts were present for carbon fiber head plates (Figure 3-4). For these 
reasons, we utilized carbon fiber head plates for all L-QMPM imaging studies. 
Figure 3-4: CT images with corresponding isodose lines for mice with no head plate, 
carbon fiber head plate, and titanium head plate.  
3.3.2 AML and ALL alterations result in increased vessel density, reduced 
blood flow, and reduced WIStissue  
We split L-QMPM imaging data into different relative low and high leukemic 
burden groups using PB measurements based on the timing of changes in single vessel 
blood flow with the onset of ALL or AML (Figure 3-5). A single measurement time-point 
from each mouse, typically matching the highest untreated disease burden was used for 
analysis of all imaging parameters for pretreatment analysis. 
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Figure 3-5: (A) Photos of mice with longitudinal cranial windows and  L-QMPM Images of 
GFP+ AML cell growth (Green) in the calvarium at  4, 6, and 10 days post AML injection 
shown with corresponding percentages of AML in the peripheral blood. (B) Single-vessel 
blood flow values for WT mice and mice with varying percentages of leukemia in PB. 
Mice bearing ALL were imaged 7-8 days after ALL injection and mice bearing AML were 
imaged longitudinally 9, 11, and 14 days after AML injection. 
To understand the differences between the timing of single-vessel blood flow 
changes in mice bearing AML or ALL, we characterized the growth kinetics of leukemia 
in the PB, femur, and calvarium. No significant time-matched differences in the 
percentage of leukemia in the PB of mice were found between mice bearing ALL and 
AML post leukemia-cell injection (P=0.5757). However, in the calvarium, we observed 
significantly higher engraftment of ALL compared to AML (P=0.014). Similar differences 
were found in the femur bone marrow (P=0.0330). The data suggest that differences in 
vascular function may be due to differences in the onset of leukemia engraftment in the 
calvarium and femur bone marrow (Figure 3-6).  
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Figure 3-6: The percentage of GFP+ ALL or AML cells in total cells for (A) peripheral 
blood, (B) crushed calvarium marrow, and (D) crushed femur marrow samples 4, 6, and 
7 days post AML or ALL injection. Measurements were taken using flow cytometry.(C) 
Comparison of the percentage of GFP+ ALL or AML cells in total cells for peripheral 
blood, crushed calvarium marrow, and crushed femur marrow samples taken from 
matching mice harvested 6 and 7 days after AML or ALL injection.  
 Reduced vascular diameter, increased vessel density, and reduced single-vessel 
blood flow were observed in mice bearing leukemia at both low and high leukemic 
burden compared to WT mice (Figure 3-7). BMV changes at low disease burden 
coincided with decreased WISwhole for mice bearing leukemia compared to WT mice 
(P=0.0178 and P=0.0018, respectively). We observed decreases in Kep and increases in 
νec in mice bearing AML at low leukemic burden compared to WT mice (P<0.0001 and 
P=0.0412, respectively).  
At high leukemic burden, we observed decreases in WIStissue for mice bearing 
ALL and AML compared to WT mice (P=0.0001 and 0.0001, respectively). We 
additionally observed decreased Ktrans at high AML burden (P<0.0001, Figure 3-8). 
Significant differences for time-lapsed imaging parameters in mice bearing leukemia at 
high disease burden included decreased WIStissue, WISwhole, PHwhole, PHblood, Kep, as well 
as increased νec compared to WT mice (Table 3-1). The most effective time-lapsed 
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imaging parameter to distinguish between mice bearing leukemia and WT mice was 
WISwhole (Figure 3-9). 
Figure 3-7: (A) Top images: L-QMPM images of GFP+ leukemia (green) and second 
harmonic generation from the collagen in the bone (blue); bottom images: L-QMPM 
images of BMV blood pool fluorescence from QtrackerTM 655 vascular labels (white). 
Plots of L-QMPM measurements of (B) mean vessel diameter, (C) mean vessel density, 
and (D) single-vessel blood flow for WT mice, and mice bearing low and high burdens of 
AML or ALL as measured by the percentage of leukemia in the peripheral blood. 
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Figure 3-8: (A) Dextran fluorescence from extravascular tissue ROIs used for time 
lapsed images from a WT mouse, and mice bearing AML or ALL. Solid lines indicate the 
corresponding fitting function used for compartmental modeling. L-QMPM 
measurements of (B) WIStissue and (C) Ktrans for WT mice and mice with varying ALL or 
AML burdens measured through PB sampling. 





Figure 3-9: Receiver operating characteristic curve for a variety of L-QMPM parameters 
from L-QMPM images of untreated WT mice and untreated mice bearing AML and ALL.  
 We measured the percent signal contribution to PHwhole from the extravascular 
tissue ROI, to better understand peak height measurements in DCE imaging. Mean 
signal contribution was 55.7±16.7%, 64.9±3.7%, and 71.7±20.7% for untreated WT 
mice, and mice bearing ALL or AML, respectively. We observed no correlation between 
PHwhole and vascular density using data from untreated WT mice and mice bearing AML 
and ALL. (R2=0.005, P=0.5235, Figure 3-10). 
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Figure 3-10: (A) The percentage contribution of the extravascular tissue ROI region 
fluorescent signal to the total signal in PHwhole for WT mice, and mice bearing AML or 
ALL. (B) A correlation plot of PHwhole and vessel density showing no significant non-zero 
correlation between the parameters. 
3.3.3 Longitudinal validation, leukemia growth, and the effects of TBI on 
the bone marrow vasculature 
 We observed no significant differences in any imaging parameters in WT 
untreated mice between imaging time-points (Table 3-2). Additionally, no significant 
differences in any of the imaging parameters or leukemia PB measurements were 
observed prior to TBI treatments in treatment subgroups with matching types of disease, 
validating longitudinal and cross-group comparisons post-treatment (Table 3-3 & Table 
3-4).
 Treatment intervention for mice bearing AML and ALL was performed 
approximately when the percentage of leukemia in the PB reached the level where 
changes in BMV function were observed. An additional group of mice were treated at 
higher ALL burden to observe the effects of TBI after ALL had caused significant 





Table 3-2: The imaging parameters for WT mice during treatment 
 
 #-PB samples were not taken in mice bearing ALL after RT as an appropriate number of 
cells could not be obtained from the maximum sampled blood volume 
†-Significantly different from pretreatment time-point P<0.05 
¶-Significantly different from 2 days post-treatment time-point P<0.05 
* -Significantly different from no RT group P<0.05 
§-significantly different from 2Gy treatment group P<0.05 
††-Significantly different from pretreatment time-point P<0.001 
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¶¶-Significantly different from 2 days post-treatment time-point P<0.001 
**-Significantly different from no RT group P<0.001) 




Table 3-3: The imaging parameters for mice bearing AML during treatment 
#-PB samples were not taken in mice bearing ALL after RT as an appropriate number of 
cells could not be obtained from the maximum sampled blood volume 
†-Significantly different from pretreatment time-point P<0.05 
¶-Significantly different from 2 days post-treatment time-point P<0.05 
* -Significantly different from no RT group P<0.05 
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§-significantly different from 2Gy treatment group P<0.05
††-Significantly different from pretreatment time-point P<0.001
¶¶-Significantly different from 2 days post-treatment time-point P<0.001
**-Significantly different from no RT group P<0.001





Table 3-4: The imaging parameters for mice bearing ALL at low disease burden during 
treatment 
#-PB samples were not taken in mice bearing ALL after RT as an appropriate number of 
cells could not be obtained from the maximum sampled blood volume 
†-Significantly different from pretreatment time-point P<0.05 
¶-Significantly different from 2 days post-treatment time-point P<0.05 
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* -Significantly different from no RT group P<0.05
§-significantly different from 2Gy treatment group P<0.05
††-Significantly different from pretreatment time-point P<0.001
¶¶-Significantly different from 2 days post-treatment time-point P<0.001
**-Significantly different from no RT group P<0.001















































Figure 3-11: The pretreatment values for WIStissue in WT mice, mice bearing AML, mice 
bearing ALL at high disease burden, and mice bearing ALL at low disease burden from 
tables Table 3-2, 3-3, 3-5, and 3-4 respectively. 
 
Table 3-5: The imaging parameters for mice bearing ALL with high disease burden 
before and 2 days post treatment 
#-PB samples were not taken in mice bearing ALL after RT as an appropriate number of 
cells could not be obtained from the maximum sampled blood volume 
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 Changes in local disease burden, vascular morphology and vascular leakage of 
Qtracker 655 blood pool agent extravascular accumulation could be clearly observed in 
large tiled images of the calvarium (Figure 3-12).  
Figure 3-12: Left: images of AML (Green) and second harmonic generation from the 
collagen in the bone (blue); right: maximum intensity projections of QtrackerTM 655 
vascular label (white). Images of 2 Gy and 10 Gy TBI are shown depicting substantial 
vascular leakage and reduction in AML burden 2 days after TBI. 
 We observed increases in mean vessel diameter, for all mice 2 days after 2 Gy 
and 10 Gy TBI as well as 5 days after 10 Gy TBI compared to that in pretreatment time-
points and untreated mice. For mice bearing AML or ALL, we observed increases in 
single-vessel blood flow 2 days after 2 Gy TBI and 10 Gy TBI compared to levels in 
pretreatment time-points and untreated mice. Compared to untreated mice, increases in 
single-vessel blood flow were observed 5 days after 10 Gy TBI treatments for mice 
bearing leukemia. We observed decreases in vessel density 2 days after 10 Gy TBI for 
mice bearing leukemia, compared to that in pretreatment time-points and, for mice 
bearing ALL, untreated mice. Decreases in vessel density were also observed 5 days 




untreated mice. Decreases in vessel density and increases in vessel diameter were also 
observed 5 days after 10 Gy TBI compared to 2 Gy for all mice (Figure 3-13). We 
observed similar trends between femur histology, calvarium histology, and L-QMPM 
imaging of the BMV for vessel diameter and vessel density measurements (Figure 3-14). 
  
 
Figure 3-13: The effects of TBI on mean vessel diameter, vessel density, and single-
vessel blood flow for WT mice, and mice bearing ALL and AML (∗P < .05, ∗∗P < .01, 
∗∗∗P < .001, ∗∗∗∗P < .0001, compared to pretreatment time-point: †P < .05, ††P < .01, 
†††P < .001, ††††P < .0001, compared to 2 days post-treatment time-point: ¶P < .05, 
¶¶P < .01, ¶¶¶P < .001, ¶¶¶¶P < .0001). 
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Figure 3-14: (A) Top: Femur histology sections stained for GFP+ AML cells (purple) and 
CD31 endothelial cells (blue) (top); middle: femur hematoxylin and eosin stained 
sections (middle); bottom: skull stained for hematoxylin and eosin sections (bottom). 
Vessel dilation was observed 5 days after 10Gy TBI for WT mice and mice bearing AML. 
(B) Mean vessel density measurements from L-QMPM imaging of mice with matching
conditions to histology. (C) Vessel density scoring of individual vessels in CD31+
endothelial stained femur sections. Two different image locations were used for vessel
scoring. (D) Vessel diameter measurements from L-QMPM imaging of mice with




3.3.4 RT increased drug delivery potential to the healthy and leukemic 
bone marrow  
 We observed increases in WIStissue for all mice 2 days after both 2 Gy and 10 Gy 
TBI compared to either pretreatment time-points, or untreated mice (Figure 3-15). 
Percent increases in WIStissue mean values ranged from 39% to 81% for WT mice and 
139% to 227% for mice bearing leukemia compared to pretreatment. Similar increases 
post-treatment for Ktrans and Kep were observed. We observed increases in WIStissue 5 
days after 10 Gy TBI for mice bearing leukemia compared to untreated mice, and, for 
mice bearing ALL, pretreatment time-points. We additionally observed significant 
increases in WIStissue 5 days after 10 Gy TBI compared to 2Gy for mice bearing AML or 
ALL (mean percent increases of 165% and 188%, respectively). We found significant 
decreases in WIStissue prior to treatment intervention in mice bearing AML or mice 
bearing ALL treated with 10 Gy at high disease burden compared to WT mice (P=0.0279 
and 0.0003, respectively), demonstrating that increases in WIStissue after TBI occurred in 
healthy or leukemic bone marrow microenvironments (Figure 3-16). We observed 
increases in PHtissue and νec after TBI at a variety of doses and time-points likely due to 
changes in cellularity (Table 3-2, 3-3, 3-4, & 3-5). Similar results are observed in DCE 
imaging [52]. 
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Figure 3-15: Images of AML (green) and second harmonic generation from the collagen 
in the bone (blue) (far left). Images of Qtracker™ 655 vascular label (red) (left middle). 
Images of dextran (white) from the first frame after injection of dextran (right middle). 
Images of dextran (white) from the 12th frame after dextran injection (far right). A dose of 
10 Gy TBI was given to the imaged mouse. Below the images, plots of fluorescent 
intensity values from the extravascular tissue ROI taken from time-lapsed images of 
dextran from 2 separate mice treated with either 10Gy or 2 Gy TBI are shown. The 
plotted data from the mouse receiving 10Gy matches the images above. Solid lines 





Figure 3-16: The effects of TBI on WIStissue, and  Ktrans for WT mice and mice bearing 
ALL or AML. (∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001, compared to pretreatment 
time-point: †P < .05, ††P < .01, †††P < .001, ††††P < .0001, compared to 2 days post-
treatment time-point ¶P < .05, ¶¶P < .01, ¶¶¶P < .001, ¶¶¶¶P < .0001 Tukey’s post hoc 
comparison) 
 A summary of the effects of TBI is shown in Figure 3-17. We found positive linear 
correlations with WIStissue for Ktrans, Kep, νec, single-vessel blood flow, and mean vessel 
diameter, while no correlation was found for vessel density (Figure 3-18).  
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Figure 3-17: A summary of the response of WT mice, and mice bearing ALL and AML to 
2 Gy and 10 Gy TBI treatments. Arrows indicate a significant increase or decrease 
compared to pretreatment time-points, orange indicates a significant increase compared 
to the untreated group, and blue indicates a decrease compared to the untreated group 





Figure 3-18: Linear correlation plots for various L-QMPM imaging parameters plotted 
with data from the time-point 2 days after TBI treatments. A single image time-point was 
used per mouse for linear correlation calculations. 
3.4 Discussion 
 We developed L-QMPM imaging to measure several parameters that quantified 
the BMV and drug delivery potential before and after RT. Decreased WIStissue, WISwhole, 
PHwhole, Kep, single-vessel blood flow and mean vessel diameter, as well as increased 
vessel density and νec were observed with the onset of leukemia. WISwhole was the most 
effective contrast-based, time-lapsed imaging parameter to identify mice bearing 
leukemia. As hypothesized, 2 Gy and 10 Gy TBI treatments increased WIStissue, Ktrans, 
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and mean vessel diameter in WT mice and mice bearing leukemia 2 days after TBI. We 
also observed increased single-vessel blood flow for mice bearing AML and ALL. 
Changes in BMV morphology and function were observed 5 days after 10 Gy TBI, while 
2 Gy caused minimal changes. Linear correlations between WIStissue and vessel 
diameter, single-vessel blood flow, Ktrans, νec and Kep were found, while vessel density 
was not correlated with WIStissue.  
 DCE imaging analysis applies mathematical models to or infers the BMV 
changes that influence the delivery of contrast agents. We calculated WISwhole and 
PHwhole as measurements commonly interpreted as the volumetric tissue blood flow rate, 
and tissue blood volume for DCE imaging [42]. Several studies using DCE imaging 
identified changes in PHwhole or similar mathematically modeled parameters to be 
positively correlated with vessel density and have proposed DCE imaging as an 
alternative method to quantify vessel density in the untreated malignant bone marrow 
[53, 97]. This circumstance is desirable as it would reduce the need for invasive bone 
marrow biopsies to quantify vessel density, which is a prognostic marker for tumor 
aggressiveness [98]. However, in this work, we found no correlation between PHwhole and 
vessel density with leukemia onset likely due to the reduction in mean vessel diameter 
present in mice bearing leukemia. Additionally, over half of the fluorescent signal 
contributing to PHwhole was from the extravascular ROI, suggesting that PHwhole 
measurements may be significantly influenced by leakage of contrast into the 
extravascular tissue. Our results demonstrate that positive correlations of PHwhole with 
vessel density or vessel volume cannot be assumed without pathological validation, and 
that mathematical modeling should be used to account for signal contributions from the 




 We identified WISwhole as the most effective time-lapsed imaging measurement to 
identify mice bearing leukemia. As WISwhole is primarily a measurement of volumetric 
blood flow, it will be closely related to mean vessel diameter, vessel density, and single-
vessel blood flow, which are all affected early in leukemia progression. This enables 
WISwhole to better identify mice bearing leukemia than other contrast-based time-lapsed 
imaging parameters, which are less sensitive to early vascular alterations.  
 Because WISwhole is primarily a measurement of volumetric blood flow, it is 
enticing to infer improved drug delivery potential when increases in WISwhole are 
observed. However, we observed that changes in WISwhole and WIStissue did not occur at 
the same disease burden. Additionally, changes in WIStissue were observed in WT mice 
after TBI, but no changes were observed in WISwhole. Our results demonstrated that 
WISwhole may not accurately identify changes in drug delivery potential, likely because 
WISwhole is a convolution of signals from vascular and extravascular tissues. These 
observations identified the importance of validating drug delivery potential when changes 
in DCE imaging parameters are observed.  
 Increases in WIStissue 2 days after TBI in WT mice were accompanied only by 
increases in Ktrans and mean vessel diameter, suggesting that increases in WIStissue were 
due to increased vascular permeability or increases in vascular surface area, which 
commonly influence Ktrans [48]. Similar alterations in Ktrans after TBI have been observed 
previously using DCE-MRI [52]. For mice bearing leukemia, increases in blood flow after 
TBI may also contribute to increased WIStissue. Similar observations of improved tissue 
drug perfusion after RT have been made in solid tumor models [27, 28], suggesting that 
the leukemic BMV and solid tumor vasculature may have similar responses to RT. 
These results suggest that increased WIStissue may be found shortly after a variety of TBI 
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doses, and directly demonstrate the role of the BMV in contributing to improved cellular 
chemotherapy uptake after LDRT that is identified in Chapter 2.  
 Although we observed similar changes in WIStissue 2 days after 2 Gy and 10 Gy 
TBI, the duration of the changes was different. These finding suggests that the window 
of opportunity for synergistic combination therapy with therapeutics after reduced-
intensity TBI regimens may be smaller than with standard myeloablative regimens of TBI 
[99]. We observed significant changes in vessel density and vessel diameter 5 days after 
10 Gy TBI compared to 2 days, while no significant differences were noticed in WIStissue. 
These data suggest that maximum BMV morphological changes after TBI may occur 
later than the maximum increases in WIStissue. These findings are in agreement with 
other studies observing vasodilation and macromolecular contrast leakage 4-7 days after 
myeloablative doses [100, 101]. Future studies should identify how long-term vascular 
damage after myeloablative TBI and bone marrow transplantation influence drug 
delivery potential.  
 We observed decreases in vessel density 2 days after 10 Gy treatment for mice 
bearing leukemia, but not for WT mice, suggesting that the leukemic BMV may have 
increased radiosensitivity. Newly formed immature vessels have been shown to be 
sensitive to RT [102, 103] and more mature vascular structures have been found after 
fractionated RT in solid tumors [104]. This suggests that the appropriate RT treatment 
may be able to preserve mature vessels, while eliminating newly formed vessels present 
from leukemia signaling. Synergistic effects have been observed with RT and vascular 
based therapeutic agents for solid tumors [105], making combination therapy an 
attractive option for the treatment of leukemia. Future studies employing dose 




vascular system, and whether enhancements to drug delivery potential are observed 
after successive fractions of LDRT.  
 Although L-QMPM is useful to accurately assess drug delivery potential, it is 
limited to preclinical models, making DCE imaging modalities such as MRI or CT 
necessary for clinical translation. In this work, we provide direct observations of BMV 
morphology and function, as well as measurements used in DCE imaging. These 
observations will be invaluable for interpretation of DCE imaging of the bone marrow. 
3.5 Conclusion 
 We identified WISwhole as the most effective parameter to distinguish between WT 
mice and mice bearing AML or ALL. This suggests that DCE imaging should focus on 
the rate of initial increase in whole tissue contrast signal during time-lapsed imaging as a 
biomarker for leukemia. Our results show that the response of the leukemic BMV to neo-
adjuvant RT improves drug delivery to the bone marrow by improving blood flow and 
increasing drug permeation through the BMV to the extravascular tissue. 
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Chapter 4: In vivo assessment of the tumor 
vascular response to radiotherapy using a 
macroscopic dynamic fluorescent contrast 
enhanced imaging system 
This chapter is based largely on the following published work:  
© 2020 IEEE. Reprinted, with permission, from Nouizi F, Brooks J, Zuro DM, 
Madabushi SS, Moreira D, Kortylewski M, Froelich J, Su LM, Gulsen G, Hui SK. 
Automated in vivo Assessment of Vascular Response to Radiation using a Hybrid 
Theranostic X-ray Irradiator/Fluorescence Molecular Imaging System. IEEE Access. 
2020;8:93663-93670. doi: 10.1109/access.2020.2994943. The first two authors 
contributed equally to this work. 
4.2 Introduction 
 Stereotactic body radiotherapy treatment (SBRT) uses a reduced number of 
treatment fractions at higher doses (hypofractionation), typically 10-20 Gy/fraction to 
treat solid tumors. Compared to conventional fractionation, hypofractionation has 
significantly decreased the relative risk of local tumor progression for patients with 
squamous, non-small cell lung cancer resulting in a 27% reduction in relative risk of local 
progression [106]. Additionally, SBRT has been shown to be tolerable and effective in 
patients for a variety of solid tumor cancers [107]. There has recently been much debate 
over whether the traditional linear quadratic model, which assumes cell death arises 




of SBRT or whether tumor vascular damage contributes to indirect tumor cell death 
through a loss of blood supply to the tumor [108-111]. Histological evaluations have 
provided evidence for extensive vascular damage following SBRT treatment, however 
histology is unable to perform non-invasive longitudinal assessments directly measuring 
blood flow. Since tumor recurrence with SBRT is still a common problem, longitudinal 
assessments of blood flow would be desirable because they would allow for direct 
correlation between tumor vascular response (TVR) and treatment outcome over time. 
Additionally, while the evaluation of the whole tumor is needed due to vascular 
heterogeneity, it is time consuming when analyzed by histology. Fast, whole-tumor, non-
invasive techniques that allow for whole tumor measurements of vascular function would 
be able to correlate TVR to treatment response. This would enable TVR to be 
investigated as a prognostic factor for treatment outcome in SBRT and enable a better 
understanding of the role of TVR in SBRT tumor control.  
 Initial work using intravital multiphoton microscopy by the author has observed 
large amounts of vascular heterogeneity in solid tumor models (Figure 4-1)[112]. While 
QMPM can simultaneously perform DCE imaging and observe single-vessel 
characteristics during radiotherapy, it typically requires invasive surgery and is only able 
to image a small region of tissue during DCE imaging (approximately 0.5 mm x 0.5 mm). 
Since the vascular distribution in solid tumor malignancies is highly heterogenous, 
similar fluorescent imaging techniques capable of observing contrast uptake and 
clearance over the entire tumor structure before and after radiotherapy would be 
desirable to ensure that results from the small regions imaged with QMPM are 
representative of the entire tumor. 
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Figure 4-1: Large set of 5 by 6 tiled images showing the vascular heterogeneity in an 
E0771 breast cancer tumor during live intra-vital imaging of a NOD/SCID mouse. The 
mouse was anesthetized, injected with 70kDa fluorescent dextran, and surgery was 
performed to expose the tumor for imaging using a 10x microscope objective with a 
Prairie Ultima multiphoton microscope. The tumor Vasculature is located at the periphery 
of the tumor with the center showing minimal functional vasculature. 
 One such technique that is well suited to obtain whole tumor measurements of 
blood flow is macroscopic near-infrared dynamic fluorescence imaging (DynFI) [113-
115]. DynFI is based on time-series analysis of a given fluorescent probe's 
pharmacokinetics and can be used to accurately and quantitatively measure functional 
parameters such as blood flow and vascular permeability for many clinical and 
preclinical applications [116-121]. A fluorescent agent commonly used for DynFI is 
indocyanine green (ICG). After injection, ICG rapidly binds to albumin making the 
kinetics of ICG fully governed by the temporal dynamics of albumin in vivo [122]. Using 
the FDA approved near-Infrared fluorescent agent ICG, DynFI has been used to 
characterize blood flow and vascular permeability in solid tumors making it suitable for 




 Acquiring spatiotemporal DynFI data using CCD camera-based systems typically 
yields extremely large data sets (i.e., number of pixels x dynamic time points) that 
require time consuming analysis. This hampers the practical application of this technique 
[125]. Analysis time can often be shortened by temporal or spatial dimension reduction. 
Typically, temporal dimension reduction is achieved through extraction of important 
temporal features (blood flow index, perfusion rate, mean transit time, etc.) that 
characterize pharmacokinetics [119]. However, the use of these temporal features is 
limited by their susceptibility to noise and motion artifacts [121]. Spatial dimension 
reduction of DynFI data is usually achieved by averaging DynFI signals within the tumor 
region, discarding any spatial information and ignoring vascular heterogeneity. One way 
to quickly assess the entire DynFI spatiotemporal data while preserving spatial 
information is to perform by using principal component analysis (PCA) [121, 125-129]. 
Analysis using PCA can be performed using pharmacokinetics of a wide variety of 
imaging agents in many tissues. PCA enables a rapid automated analysis of longitudinal 
data to quantitatively measure TVR, while still preserving spatial information. 
 In this chapter, I describe a first-of-its-kind theranostic CCD-based 
DynFI/microCT-guided targeted irradiator that longitudinally assesses TVR to SBRT 
treatments in tumor bearing mice. A rapid, automated data analysis method using PCA 
of the spatiotemporal data is used to extract pharmacokinetic information of ICG. 
Differences in the first and second principal component feature (PC1 & PC2) of ICG 
pharmacokinetics were found in tumors immediately before and two days after 10 Gy 
SBRT. The dose of 10 Gy was chosen as early changes in tumor vasculature have been 
seen at a wide range of doses (5-20 Gy/fraction) [11, 130]. Pretreatment and 
posttreatment data were plotted as a scatterplot in PC1-PC2 space and a classification 
algorithm based on a 99.9% confidence covariance ellipse was used to identify 
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responding (TVRpos) and non-responding (TVRneg) tumor pixels for rapid spatial mapping 
of tumor heterogeneity. Results demonstrate the ability of the theranostic system to both 
observe changes in ICG pharmacokinetics and perform fast, automated assessments of 
vascular response to SBRT. 
4.3 Materials and Methods 
4.3.1 Animal and tumor model 
 Four 10-15 week old C57/B6 mice (Strain 000664, The Jackson Laboratory) 
were subcutaneously injected in the right thigh muscle with aggressive murine oral cavity 
cancer, MOC2 cells (1x105 cells) [131] suspended in phosphate buffered saline (100 μl). 
Mice were injected 21 days before the start of imaging and treatment. Before imaging, 
the hair on the thighs and backs of the mice was removed using hair depilatory cream 
(Church & Dwight Company). During the treatment and imaging sessions, mice were 
anesthetized initially with 3% isoflurane mixed with O2 at a flow rate of 2 L/min, then 
maintained with 1.5% isoflurane at an O2 flow rate of 1.5 L/min. For imaging, an 
intravenous catheter was inserted into the tail vein to administer ICG (4.7 μg, 
approximately 0.19 mg/kg) suspended in saline (75 μl) during image acquisition. 
Pretreatment imaging was acquired just prior to radiation treatments. All mice fully 
recovered after the imaging procedure. Tumors volumes were measured by calipers 
before and two days after treatment. Tumor volume was calculated using the formula 
volume=length*width2/2. All animal experiments were performed according to City of 
Hope guidelines and approved by the Institutional Animal Care and Use Committee.  
4.3.2 MicroCT image acquisition and SBRT treatment 
 The X-ray irradiation was performed using the preclinical X-ray microCT image-




mm x 0.1 mm) using a low-dose of radiation (<50 cGy). After CT images were acquired, 
a Monte Carlo-based planning treatment simulation tool was used to establish and 
deliver the optimal image-guided 10 Gy treatment to the tumor ROI. 
4.3.3 Instrumentation and DynFI data acquisition 
 The theranostic system was built by incorporating a CCD-based fluorescence 
molecular imaging (FMI) system [132] into a commercial preclinical X-ray CT image-
guided radiation therapy platform (X-RAD SmART, Precision X-Ray, Inc.). The FMI 
system uses a 785 nm laser diode (75 mW, Thorlabs) for ICG excitation. The laser diode 
mounts and drivers were integrated into the system gantry. The drivers were operated in 
constant power mode to ensure output stability during the experiments. The laser output 
was collimated then sent towards an illumination point below the mouse using a 
galvano-mirror scanner. A cooled CCD camera (Perkin Elmer, Cold Blue) was positioned 
directly above the mouse to perform transillumination data acquisition. A sigma MACRO 
50 mm F2.8 lens was coupled to the CCD camera, providing 2280 pixels x 1528 pixels 
images. The pixels were binned during acquisition using a factor of 4, resulting in 570 
pixels x 382 pixels images with a pixel size of 0.2 mm × 0.2 mm. A computer-controlled 
filter-wheel (Tofra, Inc.) was installed between the CCD camera body and the lens. Two 
830 nm band-pass filters (MK Photonics) were stacked and used to eliminate excitation 
light at 785 nm. This filter combination was used to minimize the strong excitation 
leakage with a maximum transmission rate at the fluorophore emission wavelength (830 
nm). 
 A DynFI series of 46 images was acquired with an integration time of 10 seconds 
per frame. ICG was injected at the start of acquisition of the 5th frame. The four frames 
acquired before ICG injection were averaged and used as baseline, which was 
subtracted from the remaining 42 DynFI images. This was used to correct for both the 
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residual fluorescence signals and the excitation light leakage through the rejection filters 
(Figure 4-2) [133].  
Figure 4-2: Diagram of the theranostic system. The X-ray source is used to both perform 
CT imaging and high-dose irradiation. For DynFI, a CCD camera is positioned above the 
mouse while it is illuminated from below using a 785 nm laser and an XY Galvano-mirror 
scanner. A temperature control unit is used to maintain the laser operating temperature. 
NI USB DAQ: National Instrument USB data acquisition card. The dashed lines indicate 
USB connections. © 2020 IEEE 
4.3.4 Kinetics features extraction and visualization. 
PCA was performed using the "pca" Matlab® function, on the DynFI fluorescence 
signals within the tumor ROI and kidney ROI. Before quantifying the induced PC 
variation, the pretreatment and posttreatment pixel PC feature values were normalized 
by subtracting the mean pretreatment PC feature value for each tumor. An RGB image 
was made by assigning the normalized PC1 and PC2 feature values to the red channel 
and blue channels, respectively [125]. The green channel was set to zero. Each of the 
channels was individually converted to gray scale using the "mat2gray" Matlab® function 
then normalized to 255. Finally, the ROIs of the resulting PC-RGB image were 




4.3.5 Data representation and statistics 
 The 99.9% confidence covariance ellipse is defined based on the covariance of 
data. Its two major axes are calculated from the two-dominant data eigenvectors, while 
their magnitude corresponds to data eigenvalues. The orientation of the ellipse is given 
by the angle between the major eigenvector and the x-axis. 
 Significance measurements were calculated using Prism (V.7.01, GraphPad). A 
p-value of 0.05 or lower was considered significant. For box and whisker plots, boxes 
represent the 25th and 75th percentile, and error bars indicate the min and max of the 
data. All paired t-tests are performed using two-sided difference based statistical testing. 
4.4 Results 
4.4.1 SBRT-induced changes in pharmacokinetics of ICG 
 To monitor and quantify TVR after high-dose irradiation, we acquired a series of 
46 DynFI images before and two days after the irradiation of the tumor. We first 
analyzed the DynFI images simply using mean dynamic fluorescence signals obtained 
over the tumor ROI. Tumor ROIs from pre and two days posttreatment imaging were 
automatically segmented on the respective pre and posttreatment microCT images. The 
multimodal system is fully integrated enabling fast, accurate, and automated co-
registration of DynFI and microCT ROIs. 
 A delay in both tumor uptake and tumor clearance of ICG two days after SBRT 
treatment can be observed, while no such delays are observed in the kidney (Figure 
4-3). Additionally, the size of tumors did not change during treatment (336.1±152.7 and 
320.9±155.7 mm2, P=0.5971 Paired t-test) suggesting any changes in ICG kinetics were 
related to tumor biology rather than tumor geometry changes. Post-irradiation tumor ICG 
kinetics showed a slight delay during the ICG uptake compared to the pre-irradiation 
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kinetics. However, a considerable delay was seen in the ICG clearance from the tumor. 
Significant increases in averaged ICG retention was observed in tumors, resulting in a 
40.5±16.1% decrease in the exponential decay parameter of ICG after it had reached 
peak concentration (P=0.0405 Paired t-test n=4). As control, we analyzed the DynFI 
signal from the left kidney. The kidney ROI was determined by comparison to an open 
source mouse atlas [134]. No significant variation in the half-life of ICG decay was seen 
for the kidney ROI. This suggests that changes in ICG dynamics of the tumor after 
treatment are due to vascular damage with SBRT therapy (Figure 4-3)[10]. 
Figure 4-3: Representative ICG Kinetics (a) pretreatment and (c) posttreatment gray 
scale ambient-light images (left) and DynFI images acquired at 40 s, 60 s, 130 s, 350 s, 
and 450 s superimposed onto gray scale ambient-light images (right). DynFI images are 
presented using a logarithmic scale for better visualization. Ambient-light images (left) 
show the locations of the tumor ROI (solid-line) and the kidney ROI (dashed-line) used 
for analysis. (b) The plotted mean fluorescence intensity values of DynFI data for (b) the 
tumor ROI and (d) the kidney ROI for pretreatment (blue) and two days posttreatment 





4.4.2 SBRT-induced changes in the principal components 
 Taking DynFI pixel data, we obtained a simplified spatiotemporal feature 
representation by PCA analysis. Only the first two projected PC features (PC1 and PC2) 
were evaluated, as they were shown to be proportional to the area under the kinetic 
curve and to the exponential decay parameter of ICG, respectively [121]. The additional 
44 components were  discarded since they were sensitive to image noise and have not 
been shown to directly represent ICG kinetics [121]. Spatial mapping of the DynFI 
spatiotemporal pharmacokinetics of ICG using PC space mapping allowed for a straight-
forward observation of SBRT-induced TVR (Figure 4-4). A clear change in normalized 
PC1 and PC2 feature values for the tumor are seen after SBRT treatment, while no 
change is observed for kidney. Nearly significant and significant differences in mean 
normalized whole-tumor PC feature values were observed for PC1 (P=0.0559 Paired t-
test n=4) and PC2 (P=0.0432 Paired t-test n=4) respectively (Figure 4-5). 
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Figure 4-4: PC feature-based analysis of the DynFI data obtained from the mouse 
shown in Figure 4-3. Normalized time-series of ICG fluorescence intensity for all 
individual pixels in (a) the pretreatment tumor ROI (2838 pixels) and (c) the two days 
posttreatment tumor ROI (2853 pixels). PC-RGB images of normalized PC1 and PC2 
feature values superimposed on ambient-light images are shown (b) before and (c) two 
days after 10Gy SBRT treatment. The normalized PC1 and PC2 feature values were 
assigned to the red and blue channels, respectively. Green intensities were set to zero. 
A clear change from blue to red can be seen from pretreatment to two days 
posttreatment, showing TVR. Box and whisker plots of normalized PC feature values for 
(e) PC1 and (f) PC2 tumor and kidney ROIs from the corresponding pretreatment and
two days posttreatment DynFI data. An increase in normalized PC1 feature values and a
decrease in normalized PC2 feature values are seen in the tumor posttreatment, while





Figure 4-5: Box and whisker plots comparing the pre and two days posttreatment 
normalized (a) PC1 and (b) PC2 feature values for all four mice. The mean whole-tumor 
normalized (c) PC1 and (d) PC2 tissue values are shown along with the corresponding 
paired t-test. © 2020 IEEE 
4.4.3 Automated assessment of SBRT TVR response 
 After observing distinctions between PC feature values before and after SBRT 
tumor treatments, we sought to create an automatic analysis process to quantify the 
degree of SBRT-induced TVR. To do this, pretreatment and posttreatment scatter plots 
of normalized PC1 and PC2 feature values were generated.  
 Tumor pixels were classified as non-responding, partially responding, or fully 
responding based on their pretreatment and posttreatment normalized PC1 and PC2 
feature values unlikelihood. To perform this classification, a 99.9% confidence 
covariance ellipse was calculated for the pretreatment tumor pixels [135]. Posttreatment 
105 
tumor pixels were identified as tumor vascular response positive (TVRpos) if they were 
outside of the confidence ellipse or tumor vascular response negative (TVRneg) if they 
were inside the confidence ellipse. The classification algorithm identified mouse two as a 
partial responder with 86.5% of pixels being TVRpos and mouse three as a complete 
responder with 100% TVRpos pixels. The spatial location of TVRpos and TVRneg pixels 
were displayed for rapid identification of TVR spatial heterogeneity. Results demonstrate 
the ability of the classification algorithm to effectively measure TVR caused by SBRT 
(Figure 4-6).
Figure 4-6: Automated classification of TVR using a confidence covariance Ellipse 
algorithm. Scatter plots of normalized PC1 and PC2 feature values for (a) mouse two 
and (c) mouse three are shown. The normalized PC feature values from pretreatment 
images (PRE) are shown as black dots. The classification algorithm calculated a 99.9% 
confidence covariance ellipse (dashed line) from pretreatment data, which was used to 
classify the posttreatment pixels as TVRpos (blue) and TVRneg (red). Ambient-light 
posttreatment images of (b) mouse two and (d) mouse three with the overlaid tumor ROI 





4.5 Discussion  
 In this work we demonstrated the effects of SBRT on ICG tumor perfusion using 
longitudinal in vivo DynFI imaging and showed that SBRT leads to delayed clearance of 
tumor bound ICG. To our knowledge this is the first preclinical report using a multimodal 
theranostic system combined with automated analysis to monitor spatiotemporal TVR to 
SBRT. The effects of SBRT were quantified using PCA to assess TVR heterogeneity. 
Significant increases in PC1 and decreases in PC2 feature values were seen in treated 
mice. Principal component analysis was used to identify tumor pixels as TVRpos and 
TVRneg. Data acquisition and principal component analysis could be performed right after 
treatment and allows for rapid treatment and imaging without moving the animal. Rapid 
data acquisition and analysis of early TVR will help determine whether additional 
treatments are needed for tumor control. The developed system will enable correlation of 
TVR to metastatic and local tumor control during radiation therapy. 
 Dynamic Fluorescence imaging of ICG can detect changes in tissue perfusion. 
This is crucial in solid tumors where the efficiency of blood flow through the tumor likely 
contributes to the number of circulating tumor cells (CTCs) in the blood, potentially 
contributing to metastasis. The presence of functional tumor vasculature plays an 
integral role in the mobilization of CTCs [5]. The number of CTC’s after radiation therapy 
are elevated, but significantly less in patients with hypofractionated radiation therapy 
compared to conventional radiation therapy [136, 137]. However the degree to which 
radiation therapy contributes to metastasis through the migration of irradiated tumor cells 
is of some debate, as irradiation has been shown to promote the growth of previously 
dormant metastatic clones through cellular signaling [138, 139]. Longitudinal observation 
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of tumor perfusion correlated to both CTCs and metastatic occurrence after SBRT will 
give further insight into this area. 
The impact of vascular function on local tumor control post SBRT has recently 
been of much debate. Vascular damage with high-dose SBRT contributes to hypoxia 
and nutrient deprivation, but the degree to which this contributes to local tumor control 
has not been fully explored. It has been shown that high-dose single fraction SBRT has 
led to indirect cell death in multiple preclinical tumor types. Poor oxygen and nutrient 
perfusion as well as reperfusion injury have been proposed as causes of indirect cell 
death [110, 140]. However, other studies have observed that endothelial/stromal cell 
radiosensitivity had no influence on the amount of radiation needed to induce local tumor 
control of xenografted human tumors, but affected the regrowth rate of relapsed tumors 
[141]. Other studies have observed similar findings, but also found that increased tumor 
cell radiosensitivity resulted in increased tumor control [142, 143]. These studies 
demonstrate the importance of accurate measurements of tissue perfusion for radiation 
therapy related studies. Direct correlation between tissue perfusion and tumor control 
should be performed in multiple tumor types to understand the effects of radiation-
induced TVR. 
Current imaging modalities used to assess TVR in preclinical studies have some 
limitations [11]. For example, DCE MRI [144] and Nuclear Imaging [145] are expensive 
and require constraining scheduling for longitudinal preclinical imaging studies. Although 
already integrated into the irradiator, CT is limited by its low sensitivity and raises dose 
accumulation concerns [146]. Ultrasound, is user dependent, requires direct tissue 
contact and dedicated instrumentation [147]. As an alternative, we have presented a 




irradiator for in vivo monitoring of the spatiotemporal TVR. The system can assess whole 
tumor vascular heterogeneity longitudinally in response to SBRT.  
4.6 Conclusion 
 In conclusion, DynFI imaging will allow for longitudinal whole-tumor observations 
of early TVR and tumor perfusion. This will enable a better understanding of how the 
tumor vasculature affects metastasis, tumor growth, and local tumor control. Our recent 
study modeled from solid tumor data taken from QMPM imaging revealed radiation-
induced vascular alterations may modulate hypoxia, adversely affecting tumor control 
probability in successive fractionated treatments [112]. DynFI imaging combined with 
QMPM will provide a novel set of tools to observe the relationship between the tumor 
vasculature, tissue perfusion, and local tumor control for conventional and 
hypofractionated radiation therapy.  
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Chapter 5: Summary and Future Work 
5.1 Summary 
 In this work two novel DCE imaging systems capable of identifying longitudinal 
changes in the healthy and malignant vasculature during radiotherapy were developed. 
The development of L-QMPM allowed for a thorough characterization of the BMV that 
included observations of angiogenesis, poor perfusion, and decreased drug delivery to 
the leukemic bone marrow. Furthermore, the assessment of low and high dose RT 
showed transient increases in drug delivery several days after RT likely due to 
vasodilation and increased blood flow in mice bearing leukemia. Changes in drug 
delivery after RT increased cellular uptake of chemotherapy, leading to increased 
survival for mice bearing ALL in combination therapy. Results demonstrate the 
importance of the BMV in the outcome of leukemia treatments. A summary of the effects 





Figure 5-1: A diagram of the healthy, leukemic, and leukemic irradiated BMV showing 
changes in vascular morphology, blood flow, vascular permeability, and drug delivery 
between healthy mice, mice bearing leukemia, and mice bearing leukemia given RT. 
  Macroscopic DynFI enabled observations of early vascular changes during 
radiotherapy of solid tumors. The integration of this system into a commercial irradiator 
has the potential to allow for early observations (minutes to hours) of changes in the 
uptake and clearance of ICG after RT. The semi-automated analysis using PCA 
identified pixelwise changes in the uptake and clearance of ICG from solid tumors. 
DynFI with PCA represents a powerful tool that can be useful to rapidly identify changes 
in the tumor while preserving spatial information needed to understand the heterogeneity 
of the tumor vasculature.  
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5.2 Future Work 
L-QMPM can perform direct validations of macroscopic DCE modeling through
direct observation of the underlying vasculature. Several models exist for macroscopic 
DCE imaging [148], however the accuracy of such models has largely not been tested in 
a single platform capable of directly observing the underlying vascular structure while 
performing DCE imaging [47]. Future studies directly comparing L-QMPM imaging to 
DCE MRI may help better understand the differences between DCE imaging in the 
clinical and preclinical observations in the malignant bone marrow.  
 Potential biological applications for L-QMPM include 1) studying long term 
vascular damage and repair during hematological bone marrow transplant regimens 
[101] with radioprotectant therapeutics, 2) characterizing the BMV for different
applications such as sickle cell disease, solid tumor metastasis, osteoporosis, or aging, 
and 3) studying the solid tumor vasculature in mice with the development of a window 
chamber [26] in combination with DynFI imaging. 
 Future work using DynFI macroscopic imaging should perform a thorough 
characterization of the changes in ICG uptake and clearance for standard fractionation 
and hypofractionated radiotherapy. This would allow for a powerful characterization of 
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